

INDEX

Volume Fourteen—January through December 1980

DRUG INTELLIGENCE AND CLINICAL PHARMACY

JANUARY	Pages 1- 80	JULY/AUGUST	Pages 465-576
FEBRUARY	Pages 81-160	SEPTEMBER	Pages 577-656
MARCH	Pages 161-240	OCTOBER	Pages 657-736
APRIL	Pages 241-320	NOVEMBER	Pages 737-816
MAY	Pages 321-400	DECEMBER	Pages 817-896
JUNE	Pages 401-464		

A

Abbreviations, letter of comment, 552

Abish, Marvin (author) letter, comments on formation of ACCP, 790

Acebutolol, effect on blood glucose, 47; pharmacokinetics, 746

Aceonocumol, effect on phenytoin, 672

Acetaphate, residue in tomatoes, 78

Acetaminophen, in neurology (CTF) 721; in toxicology (CTF) 381, 443; renal tubular necrosis and liver damage, 431; in neurology (CTF) 228; poisoning, antidote adsorption by charcoal (ab 15), 635

Acetazolamide, in neurology (CTF) 797; metabolic acidosis, case report, 371, 795

N-Acetylcysteine, adsorption by charcoal (ab 15), 635; in toxicology (CTF) 147

Acid-base Disorders, in general medicine (CTF) 720

Acidosis, metabolic, acetazolamide-induced, 371

Acids, in toxicology (CTF) 873

Aene, inflammatory, efficacy study of topical erythromycin (ab 24), 637; in dermatology (CTF) 379; use of antibiotics, 498

Aerolin, inhibits adriamycin microsomal metabolism (ab 10), 634

Activated Charcoal, adsorption of methionine and N-acetylcysteine (ab 15), 635

Aeu-Dot[®], magnetic patch analgesic, misbranding, 573

Adams, P.C. (coauthor) letter, pain following iv cimetidine, 294

Adams, Thomas R. (coauthor) Impact of Patient-Specific Drug Interaction Information on Physician Prescribing Patterns, 280

Adverse Effects, cautionary statements in OTC advertising, 358; chronic therapy with theophylline, 522; hypoprothrombinemia with cefamandole, 780

Adverse Reactions, acetaminophen, thrombocytopenia (CTF) 722; N-acetylcysteine, anaphylactic reaction, 229; ACTH, brain shrinkage (CTF) 555; alcohol, hematologic abnormalities (CTF) 722; alcohol, thrombocytopenia (CTF) 644; allopurinol, nephrolithiasis (CTF) 443; allopurinol, vasculitis (CTF) 304; amantadine, side effects (CTF) 722; aminocaproic acid, renal failure (CTF) 798; aminoglycosides, nephrotoxicity, 229; aminophylline, urticaria (CTF) 147; amitriptyline, tonic-clonic seizures, 378; amoxapine, galactorrhea (CTF) 147; antiparkinson drugs, tardive dyskinesia (CTF) 381; artificial sweeteners, nonassociation with cancer of lower urinary tract (CTF) 381; aspirin, gastric ulcers (CTF) 69; aspirin, no effect on renal function (CTF) 444; aspirin, Reye's syndrome (CTF) 644; asthma, bronchospasm (CTF) 644; BCG vaccine, erythema multiforme (CTF) 555; captopril, immune complex glomerulopathy (CTF) 722; captopril, pemphigus erythematosus (CTF) 798; carbenicillin, pseudomembranous colitis (CTF) 444; cefamandole, gastrointestinal bleeding (CTF) 304; cefoxitin, reversible leukopenia (CTF) 722; chlorpropamide, RBC aplasia (CTF) 645; cimetidine, bone marrow suppression, 69; cimetidine, exfoliative dermatitis (CTF) 444; cimetidine, granulocytopenia/thrombocytopenia (CTF) 147; cimetidine, hemolytic anemia (CTF) 69; cimetidine, mental confusion (CTF) 722; cimetidine, renal function reduced (CTF) 645; cimetidine, withdrawal symptoms (CTF) 381; cisplatin, peripheral neuropathy (CTF) 304; cisplatin, positive direct antiglobulin test (CTF) 304; clofibrate, fever (CTF) 147; cloxacillin, cholestatic jaundice (CTF) 798; conjugated estrogens, nonassociation with breast cancer in replacement therapy (CTF) 722; cotrimoxazole, interstitial nephritis (CTF) 798; cyclophosphamide, congestive heart failure (CTF) 798; cytotoxic agents, update (CTF) 381; danazol, decreased thyroid function (CTF) 555; dapsone, hyperalbuminemia (CTF) 69; demeclocycline, renal impairment (CTF) 722; dextran-40, fatal anaphylactoid reaction (CTF) 444; diazepam, withdrawal symptoms (CTF) 304; diazoxide, neonatal hyperglycemia, 229; disopyramide, cholestasis (CTF) 799; disopyramide, congestive heart failure (CTF) 381; disulfiram, peripheral neuropathy (CTF) 645; dopamine, peripheral ischemia (CTF) 444; doxorubicin, risk of cardiomyopathy (CTF) 304; doxorubicin, sudden death, 229; enflurane, hepatitis (CTF) 799; epsilon-aminocaproic acid, rhabdomyolysis (CTF) 645; erythromycin estolate, biliary obstruction, 229; fenoprofen, acute renal failure (CTF) 381; fenoprofen calcium, hypersensitivity (CTF) 304; fenoprofen, thrombocytopenia (CTF) 444; flurazepam, hostility reaction, 291; furosemide, erythema multiforme (CTF) 645; gentamicin, thrombocytopenia (CTF) 722; gold sodium thiomalate, pulmonary fibrosis (CTF) 555; haloperidol, SIADH, 147; hemodialysis, cardiovascular disease (CTF) 555; heparin, hyperkalemia (CTF) 799; heparin, thrombocytopenia (CTF) 722; hepatotoxicity, drugs associated with liver disease, 229; hydralazine, hepatitis (CTF) 645; hydralazine, rise in blood pressure (CTF) 799; hydromorphone, higher incidence of adverse reactions (CTF) 645; hyperalbuminemia, acalculous cholecystitis (CTF) 304; ibuprofen, gastric mucosal injury (CTF) 444; ibuprofen, meningitis (CTF) 444; imipramine, withdrawal (CTF) 381; indomethacin, gastric perforation (CTF) 722; influenza virus vaccine, nephropathy (CTF) 147; intestinal obstruction, associated agents (CTF) 722; interstitial disease (CTF) 381; naproxen, aplastic anemia (CTF) 381; naproxen, lithium, kidney damage (CTF) 381; lithium, nephrotic syndrome (CTF) 304; lithium, psoriasis, 147; lithium, renal damage, 229; lithium, thyroid cancer (CTF) 555; lorazepam, grand mal seizures (CTF) 555; mefenamic acid, renal failure (CTF) 799; melphalan, pulmonary fibrosis (CTF) 722; methyldopa, pancreatitis (CTF) 799; metoprolol, various, 174; metoprolol, eczematous reaction, 69; metronidazole, colitis (CTF) 799; metronidazole, encephalopathy (CTF) 799; metronidazole, neutropenia 69; minoxidil, pericardial effusion (CTF) 381; mitomycin, pulmonary interstitial disease (CTF) 381; naproxen, aplastic anemia (CTF) 381; naproxen, jaundice (CTF) 722; neuroleptics, neuroleptic malignant syndrome (CTF) 555; nifedipine, pulmonary edema (CTF) 799; nitrofurantoin, hepatitis (CTF) 229; nitrofurantoin, pulmonary hemorrhage (CTF) 444; nitroglycerin, dermatitis (CTF) 69; nitroprusside, left ventricular filling pressure (CTF) 147; nonsteroidal antiinflammatory agents, renal failure (CTF) 147; oral contraceptives, arterial thrombosis (CTF) 304; oral contraceptives, nonassociation with breast cancer (CTF) 304; pentazocine, agranulocytosis (CTF) 444; phenothiazines, sudden death, 147; phenylephrine, pressor responses, 69; phenylpropanolamine, increased diastolic blood pressure (CTF) 304; phenytoin, cerebellar degeneration (CTF) 381; phenytoin, hepatic necrosis, 229; phenytoin, hypersensitivity, 147; pilocarpine, intraocular pressure (CTF) 69; pneumococcal vaccine, polyvalent, febrile systemic reaction (CTF) 147; potassium chloride, esophagitis (CTF) 304; potassium phosphate, hypocalcemia (CTF) 229; prazosin, angina (CTF) 69; prazosin, priapism (CTF) 147; procainamide, antinuclear antibodies (CTF) 229; procainamide, SLE development (CTF) 229; procaine povidone, subcutaneous nodules (CTF) 722; propylthiouracil, cutaneous vasculitis (CTF) 304; pulmonary disease, drugs inducing (CTF) 69; quinine, esophagitis (CTF) 304; quinine, myasthenia gravis (CTF) 444; quinine, thrombocytopenia (CTF) 444; quinine, disseminated intravascular coagulation (CTF) 147; reserpine, nonassociation with breast cancer (CTF) 645; rifampicin, early lesions of osteomalacia (CTF) 723; ritodrine, fetal death (CTF) 723; rosmarinic acid, hepatotoxicity (case report) 786; screening method, 23; sodium aurothiomalate, renal failure (CTF) 723; spirinolactone, skin lesions (CTF) 147; sulindac, pancytopenia (CTF) 723; sulindac, toxic epidermal necrolysis syndrome (CTF) 444; tamoxifen, hypercalcemic coma (CTF) 69; tamoxifen, thrombocytopenia (CTF) 381; tetracycline, gout (CTF) 69; timolol, bronchorrhea (CTF) 645; tobramycin, less nephrotoxic than gentamicin (CTF) 645; tolazoline, hyperchloremic metabolic alkalosis (CTF) 444; triamterene, nephrolithiasis (CTF) 147; d-tubocurarine, anaphylactic reaction (CTF) 147; vasopressin, ventricular dysrhythmia (CTF) 444; Alka-Seltzer[®], gastrointestinal hemorrhage (CTF) 873; carmustine, pulmonary fibrosis (CTF) 873; cimetidine, aplastic anemia (CTF) 873; cyclophosphamide, bladder cancer (CTF) 873; fenitanyl, hyperexcitability (CTF) 873; fluphenazine, jaundice (CTF) 873; furosemide, ototoxicity (CTF) 874; indomethacin, acute renal failure (CTF) 874; medroxyprogesterone acetate, breast cancer (CTF) 874; metrizamide, asterixis (CTF) 874; naproxen, vasculitis (CTF) 874; nitroprusside, lactic acidosis (CTF) 874; thiazide diuretics, acute cholelithiasis (CTF) 874; tolmetin, anaphylactic reaction (CTF) 874; vitamin K, cerebral thrombosis (CTF) 874

Aging, National Clearing House, information systems, 653

Ahsanuddin, K. (coauthor) Tourette's Syndrome—Treatment with Clonidine, a Centrally Acting Alpha-Adrenergic Agonist, 288

Ajmaline, in toxicology (CTF) 69

Albumin, in general medicine (CTF) 797, 871; new ultrafiltration method (ab 16) 635

Alcohol, in cardiovascular disease (CTF) 67; in general medicine (CTF) 67; in neurology (CTF) 872; in ophthalmology (CTF) 443

Alexander, Bruce (coauthor) see Taylor, Jerry A., 669

Alexander, Michael M. (author) letter, an evaluation of child-resistant prescription containers utilized by arthritic patients, 794

Allisandratos, Jane K. (coauthor) see Koren, James F., 711

Allopurinol, absorption from rectal suppositories, 789; in dermatology (CTF) 553; in neurology (CTF) 68

Alpha-Fetoprotein, appeal to prohibit marketing, 79

Alprenolol, effect on blood glucose, 47; pharmacokinetics, 46

Amantadine, in general medicine (CTF) 797; use in the elderly, letter, 377

Amato, Joseph J. (coauthor) see Weiner, Bruce, 831

Aminoclonide, in dermatology (CTF) 302

American Association of Colleges of Pharmacy, booklet released, 574; NIH research support, 398

American College of Clinical Pharmacy, abstracts from papers of first annual meeting, 632; index, 639; call for abstracts, 215; call for membership, 245; candidates for office, 744; comments (letters) 293, 294, 790; committees appointed, 167; first annual meeting, 664; funds transferred from ABCP (letter) 625; funds acknowledged (letter), 868; minutes of regents' meeting, 824; officers and regents, 658, 818; official public statement, 8; second annual meeting planned, 744

American Council on Pharmaceutical Education, endorses DICP PharmACE[®] program, 158

American Pharmaceutical Association, court judgment, 398

American Society for Pharmacy Law, installment of officers, 815

American Society of Consultant Pharmacists, executive resident position, 398; Medicaid reimbursement, 157; second mid-year conference held, 462; 10th annual meeting, 398

Amikacin, in infectious disease (CTF) 68, 643; stability in intravenous solutions, 848

Aminocaproic Acid, in hematology (CTF) 227; in neurology (CTF) 797

Aminophylline, in obstetrics/gynecology (CTF) 68; in pediatrics (CTF) 721

Amiodarone, for tachyarrhythmias (ab 4), 632

Amitriptyline, in neurology (CTF) 380; in pediatrics (CTF) 228, 798; tonic-clonic seizures in the mentally retarded, 378; in psychiatry (CTF) 873

Amoxilline, in infectious disease (CTF) 145, 442, 797

Amphetamine, in anesthesiology (CTF) 441

Amphotericin B, activity after filtration, letter, 719; comment on therapy (letter) 719; in infectious disease (CTF) 227, 720; intrathecal administration, 180; pharmacokinetics, 177; review of complications, 177

Ampicillin, freeze-thaw treatment study, 353; versus cephalothin versus cephapirin for vaginal hysterectomy (ab 26), 637

Androgens, use in hemodialysis patients, 493

Anemia, associated with renal disease, use of androgens, 493; hemolytic, phenazopyridine (case report) 290; with amphotericin B, 179; acute hemolytic with phenazopyridine, 861

Anesthesiology (CTF), amphetamine, 441; cimetidine, 145; diazepam, 67, 553; droperidol, 553; enflurane/halothane, 227; lidocaine, 379, 796; lorazepam, 145; lysine acetylsalicylate, 796; metoprolol, 302; minaxolone, 553; morphine, 642; neostigmine, 67; procaine, 302; bupivacaine, 871

Anesthetics, local, in dermatology (CTF) 441
 Angina, nifedipine, 827
 Antacids, in gastroenterology (CTF) 302, 553
 Antiarrhythmic Agents, in rheumatology (CTF) 443
 Antibiotics, admixtures, different freeze-thaw treatments, 353; in infectious disease (CTF) 379, 442; in intravenous therapy (CTF) 146; in pediatrics (CTF) 643; use in acne, 499
 Anticoagulants, oral, and drugs which alter their function, 331; oral, interactions with phenytoin, 669
 Antidiabetic Drugs see individual drug names
 Antidotes, in toxicology (CTF) 69
 Antiepileptic Drugs see individual drug names
 Antihypertensives, in cardiovascular disease (CTF) 67
 Antimony, contamination in coffee, 573
 Antithyroid Drugs, in obstetrics/gynecology (CTF) 146
 Antitubercular Agents, in pulmonary disease (CTF) 644
 Appgar, David A. (coauthor) see Copeland, Gary F., 114
 Aplastic Anemia, in hematology (CTF) 797
 Appelbaum, Steven J. (coauthor) letter, allopurinol absorption from rectal suppositories, 789
 Appreciation to Referees, 1900, 886
 Araujo, Oscar E. (author) book review, 384
 Archambault, George F. (ed) The Art of Communicating, 464; (ed) Journal Clubs and the Pharmacy Department, 400; (ed) The "Man-In-The-Plant" Problem Won't Go Away, 320; (ed) Patient Package Inserts and the Unit-of-Use (Patient Package)—An Update, 736; (ed) Pharmaceutical Pedagogy: Redundancy—An Important Tool of Teaching, 656; (ed) The Thirsty Orphans of the Drug World, 816; Pharmacy, Whither Goest Thou? Part I, 160; (ed) Medicine and Pharmacy—"Rendezvous with Time," 882; (editor) Washington News and Comments, 77, 157, 237, 317, 395, 461, 571, 653, 733, 797, 879
 Arrhythmias, use of amiodarone (ab) 4, 632
 Arsenic, in toxicology (CTF) 555
 Aspirin, enteric-coated, comparative bioavailability, 103; in cardiovascular disease (CTF) 302; in neurology (CTF) 303; in pediatrics (CTF) 146, 721; pharmacokinetics, 106; prevention of second strokes, 395
 Association for the Advancement of Medical Instrumentation, sixth annual conference, 395
 Atenolol, effect, blood glucose, 47; in cardiovascular disease (CTF) 145; pharmacokinetics, 746
 Atropine, in pulmonary disease (CTF) 721
 Ausman, R.K. (coauthor) The Application of A Freeze—Microwave Thaw Technique to Central Adipose Services, 284; (coauthor) see Holmes, C.J., 353
 Author's Guidelines, 4, 84, 162, 242, 322, 402, 466, 578, 738
 Azathioprine, in gastroenterology (CTF) 720; relapsing polycondritis, 413

B

Bacitracin, in infectious disease (CTF) 720
 Bactofen, in psychiatry (CTF) 146
 Bacterial Vaccines, in pediatrics (CTF) 443
 Ball, William D. (coauthor) book review, 565; (coauthor) letter, see Luffert, Carl H., 719
 Balentine, Ron L. (author) book review, 386
 Barbiturates, in neurology (CTF) 68, 554
 Barriere, Steven L. (coauthor) see Maddux, Michael S., 177
 Barry, W.S. (coauthor) letter, see Howse, C.R., 439
 Bauer, Larry A. (coauthor) see Blouin, Robert A., Jr., 218
 Bauman, Jerry L. (coauthor) see Kelly, Kim L., 516
 Bayliff, C.D. (author) tobramycin, 55
 BCG Vaccine, in oncology (CTF) 303
 BCNU, in oncology (CTF) 303
 Bennett, John M. (coauthor) see Loughner, John E., 861
 Benzodiazepines also see individual agents; comment on reaction, 723; withdrawal reactions, 197
 Benzotropine, in psychiatry (CTF) 228; paralytic ileus, case report, 17
 Benzyl Alcohol, hemolytic effect, 549
 Berg, Mary J. (author) Erythrocyte Lithium and the Erythrocyte: Plasma Lithium Ratio as Indicators of Mood Changes: preliminary report, 836
 Bergman, H. David (reviewer) cefaclor, 11
 Beta-blocking Agents see individual drug names; in endocrinology (CTF) 796; pharmacokinetics, 746
 Bethanechol, in pediatrics (CTF) 443
 Bickett, William J., II (coauthor) Comparative Bioavailability of Enteric-Coated Aspirin Preparations, 103
 Bioavailability, comments on evaluation, 327; enteric-coated aspirin, 103
 Biopharmaceutics, cefaclor, 11
 Bismuth Subsalicylate, in general medicine (CTF) 302
 Bivins, Brack A. (coauthor) see DiPiro, Joseph T., 57
 Black, Curtis (coauthor) see Hahn, Deborah A., 591
 Bladder Cancer, in oncology (CTF) 721
 Blanford, Marvin F. (reviewer) Nadolol, 825
 Blockstein, William L. (author) A Majority of One, 855
 Blouin, Robert A., Jr. (coauthor) Decreased Gentamicin Half-life During Peritoneal Dialysis, 218
 Bonal, Joaquin (coauthor) Trends in Clinical Pharmacy in Spain, 259
 Books Reviewed, Abstracts on Long Term Care Pharmacy (Edward D. Sumner) 233; The Anticancer Drugs (Pratt, Rudolph) 561; Applied Therapeutics for Clinical Pharmacists, 2nd edition (M.A. Koda-Kimble, B.S. Katcher, and L.Y. Young) 62; Arachidonic Acid Metabolism in Inflammation and Thrombosis (Brune, Baggioni) 449; Chronopharmacology, Advances in the Biosciences, Vol. 18 (Reinberg, Hager) 233; Clinical and Experimental Neurology, Vol. 15 (Treyer-Eadie) 383; Clinical Pharmacology and Therapeutics: A Pediatric Perspective (Bernard L. Mirkin) 61; Clinical Pharmacology and Therapeutics in Nursing (Weiner et

al.) 449; Computer Assisted Studies of Chemical Structure and Biological Functions (Stuper et al.) 562; Disposition of Toxic Drugs and Chemicals in Man—Vol. 2. Peripherally-Acting Drugs and Common Toxic Chemicals (Randall S. Baselt) 583; Drug Fate and Metabolism: Methods and Techniques, Vol. 3 (Garrett, Hirtz) 384; Drug Assessment Criteria and Methods (Bowers, Vello) 559; Drug-Induced Nutritional Deficiencies (Daphne A. Roe) 563; Drug Interactions Index 1978/79 (Eric W. Martin) 299; Drug Therapeutics—Concepts for Physicians (Kenneth L. Melmon) 232; The Essential Guide to Prescription Drugs (James W. Long) 560; The Fax-It Prescription and Medication Guide (Lawrence J. Lesko) 564; Fundamentals of Cancer Chemotherapy (Marion D. Cridland) 386; Handbook of Institutional Pharmacy Practice (Smith, Brown) 561; Handbook of Nonprescription Drugs, 6th edition (L. Luan Corrigan), 62; Handbook on Injectable Drugs, 2nd Ed (Lawrence A. Trissel) 450; The Heritage of Nuclear Medicine (Bruce et al.) 300; Human Aspects of Hospital Pharmacy Management (Hepler, Mattson) 300; Index Nominum 1990 (Swiss Pharmaceutical Society) 386; An Introduction to Human Pharmacology (J.D.P. Graham) 448; Microbial Drug Resistance, Vol. 2 (Susumu Mitsuhashi) 564; Nuclear Medicine Review Syllabus (Peter T. Kirchner) 450; Nurse's Drug Reference (Joseph A. Albanese) 385; The Pharmaceutical Codes, 11th Ed. (Pharmaceutical Press) 565; Practical Drug Therapy (Richard L.H. Wang) 363; Prescription Drugs in Short Supply: Case Histories (Michael A. Schwartz) 450; Progress in Clinical Pharmacy (Schaaf, van der Klein) 299; Recent Advances in Receptor Chemistry (Gualtieri et al.) 300; Stimulus Properties of Drugs: Ten Years Progress (Colpaert, Rosencranz) 559; Studies in Drug Utilization (Bergman et al.) 382; Topics in Therapeutics, Vol. 5 (Davies, Rawlins) 565; Workshop on Ursodeoxycholic Acid (R.H. Dowling et al.) 448; The Year Book of Dermatology—1979 (Richard L. Dobson) 384; Year Book of Drug Therapy 1979 (Leo E. Hollister) 560
 Brack, Graham (author) letter, confusing abbreviations, 552
 Bradberry, J. Chris (coauthor) book review, 232
 Bradley, Joan Marie (author) letter, correction on tiernalen, 628
 Bread, reduced calorie, FDA ruling, 734
 Breast Milk, in pediatrics (CTF) 389
 Bretylium Tosylate, in intravenous therapy (CTF) 643
 Britton, H. Lynn (coauthor) case report, phenytoin-induced hyperglycemia, 544
 Brodie, Donald C. (coauthor) see Smith, William E., Jr., 599
 Bromocriptine, in endocrinology (CTF) 67, 227, 796; in gastroenterology (CTF) 553; in general medicine (CTF) 554; in neurology (CTF) 643; in obstetrics/gynecology (CTF) 721, 872; in oncology (CTF) 68
 Brompton's Mixture, in oncology (CTF) 554
 Brown, James R. (coauthor) see Koren, James F., 252, 711
 Bryan, Candace Kendle (author) book review, 61
 Bupivacaine, in anesthesiology (CTF) 871
 Burke, Arthur W., chairman, budget and finance committee, ACCP, 167
 Butorphanol, in neurology (CTF) 228
 Butyl Nitrate, abuse problem, 358
 Butyl Nitrite, in toxicology (CTF) 555

C

Caffeine, birth defects, 572; in psychiatry (CTF) 68; possibility of warning labels, 463
 Calcium Antagonists, in cardiovascular disease (CTF) 642
 Cambridge Diet, FDA precautions, 733
 Cancer, use of hexamethylmelamine, 593
 Captopril, abrupt discontinuation in hypertensive patients (ab) 538; in cardiovascular disease (CTF) 67, 720; in pediatrics (CTF) 68; in refractory malignant hypertension, 373
 Carbamazepine, for phantom limb pain, 100; pharmacokinetic calculations, 674
 Carbenicillin Disodium, freeze-thaw treatment study, 353
 Carboprost Tromethamine, in obstetrics/gynecology (CTF) 303
 Cardiopulmonary Resuscitation, in general medicine (CTF) 797
 Cardiovascular Disease (CTF), alcohol, 67; antihypertensives, 67; aspirin, 302; atenolol, 145; calcium antagonists, 642; captopril, 67, 720; clonidine, 227, 302, 642; colestipol, 441; dopamine, 145; enalapril, 553; haptan dextran, 642; heparin, 553; hydralazine, 553, 642, 796; inotropic agents, 642; levaterenol, 379; lidocaine, 796; metoprolol, 227, 553; minoxidil, 379; molsidomine, 227; nadolol, 145, 302, 796; nifedipine, 642, 796; nitroglycerin, 553; nitroprusside, 720; prajmalum bitartrate, 642; prazosin, 441, 642, 796; propranolol, 67; quinidine, 553; spironolactone, 441; streptokinase/urokinase, 145; sulfapyrazone, 302; teprotide, 411; timolol, 302; tocinide, 796; vasodilators, 411, 553; verapamil, 302, 553, 796; warfarin, 67; digoxin, 871; dobutamine, 871; lidocaine, 871; nitroglycerin, 871
 Cardoni, Alex A. (editor) New Drug Evaluations, 11, 86, 169, 447, 585, 825
 Carmustine, in intravenous therapy (CTF) 643
 Cascio, Frank S. (coauthor) see Foster, Thomas S., 796
 Case Reports, acetazolamide-induced metabolic acidosis, 371; an allergic reaction to a vitamin B₁₂ preparation, 717; asymptomatic theophylline overdose, 783; ataxia as the primary symptom of lithium toxicity, 622; captopril in refractory malignant hypertension, 373; decreased gentamicin half-life during peritoneal dialysis, 218; digoxin toxicity with hyperglycemia levels, 547; erythromycin—oral ulceration, 217; gentamicin nephrotoxicity during dosing controlled by gentamicin serum levels, 53; hallucinations from triazolam, 714;

hepatotoxicity with roxarsamin—a new antibiotic related to erythromycin, 786; hostility reaction to flurazepam, 291; hypoprothrombinemia associated with cefamandole, 780; illicit use of diphenoxylate hydrochloride to prevent narcotic withdrawal symptoms, 715; indomethacin-induced acute renal failure, 711; intravenous lidocaine in the treatment of seizures, 436; mesoridazine and benzotropine mesylate induced paralytic ileus, 17; Morgani-Stokes Adams Syndrome, 56; phenazopyridine-induced hemolytic anemia, 290; phenytoin-induced hyperglycemia, 544; probable erythromycin ototoxicity, 623; quinidine-induced fever and hepatic dysfunction, 218; renal tubular necrosis and liver damage, a possible consequence of low dose of acetaminophen and halothane anesthesia, 431; sodium and water retention associated with indomethacin therapy, 620; tobramycin, 55; Tourette's Syndrome, treatment with clonidine, 288; toxic lidocaine levels and diminished cardiac output and prolonged infusions, 435; acquired acute hemolytic anemia secondary to phenazopyridine, 861; hepatic coma following enflurane anesthesia, 863; bleeding associated with concurrent warfarin and metronidazole therapy, 864; terbutaline sulfate overdosage, 866
 Castro, Isabel (coauthor) see Bonal, Joaquin, 259
 Caustics, in toxicology (CTF) 381
 Cefaclor, adverse reactions, 14; in infectious disease (CTF) 145, 643; in pediatrics (CTF) 721; new drug evaluation, 11; pharmacokinetics, 11
 Cefadroxil, in infectious disease (CTF) 379
 Cefamandole, case report of hypoprothrombinemia, 780; freeze-thaw treatment study, 353; in obstetrics/gynecology (CTF) 303; with tobramycin in infectious disease (CTF) 554
 Cefazolin, freeze-thaw treatment study, 353; in infectious disease (CTF) 379, 442, 872; in obstetrics/gynecology (CTF) 643
 Cefotaxime, in infectious disease (CTF) 303
 Cefoxitin, freeze-thaw treatment study, 353
 Cefuroxime, in infectious disease (CTF) 797; in ophthalmology (CTF) 146
 Cephalosporins, pharmacy education program, 272
 Cephalothin, freeze-thaw study, 353; in infectious disease (CTF) 380; versus ampicillin versus cephalin for vaginal hysterectomy (ab) 26, 637
 Cephradine, versus ampicillin versus cephalothin for vaginal hysterectomy (ab) 26, 637
 Cephradine, in infectious disease (CTF) 68; in pediatrics (CTF) 554
 Certification, specialty, 32
 Cesario, Thomas C. (coauthor) letter, see Vaziri, Nosratola D., 549
 Chemotherapeutic Agents see individual drug names
 Chloral Hydrate, in ophthalmology (CTF) 643; in toxicology (CTF) 443
 Chlorambucil, in pulmonary disease (CTF) 873
 Chloramphenicol, in ophthalmology (CTF) 146; in pediatrics (CTF) 644; in toxicology (CTF) 381; letter, interaction with phenytoin, 221
 Chloride, deficiency in infant formulas, 318
 Chlorothiazide, in renal disease (CTF) 228
 Chlorpheniramine, in general medicine (CTF) 145
 Chlorpromazine, in neurology (CTF) 721
 Cholelithiasis, in gastroenterology (CTF) 302
 Cholestyramine, in pediatrics (CTF) 68
 Choline, in neurology (CTF) 380; in psychiatry (CTF) 68
 Choline Magnesium Trisilicate, in rheumatology (CTF) 443
 Chymopapain, in neurology (CTF) 643
 Cimetidine, in anesthesiology (CTF) 145; in dermatology (CTF) 976; in gastroenterology (CTF) 67, 145, 442, 642; in intravenous therapy (CTF) 380; in neurology (CTF) 303; in obstetrics/gynecology (CTF) 303; in oncology (CTF) 303; in pediatrics (CTF) 443; interaction with diazepam (ab) 8, 633; pain following administration (letter), 294
 Cinacalcin, in dermatology (CTF) 379
 Cinacalcin, pharmacokinetics in renal insufficiency (ab) 3, 632
 Cisplatin, in oncology (CTF) 303, 554, 643, 798; lung cancer, 595; pharmacokinetics in children (ab) 5, 632
 Cleveland, Richard J. (coauthor) see Weiner, Bruce, 831
 Clindamycin, use in acne, 500
 Clinical Pharmacy see also Pharmacy Practice; cost impact of the decent clinical pharmacist, 266; credentialing, 664; in Spain, 259; team role models for pharmacy (ed) 134
 Clinical Pharmacy Case Reports, 53, 216, 288, 371, 431, 544, 620
 Clonidine, in renal disease (CTF) 721
 Clomiphene, in endocrinology (CTF) 227; in urology (CTF) 798
 Clonazepam, in neurology (CTF) 303
 Clonidine, for opiate withdrawal, 101; in cardiovascular disease (CTF) 227, 302, 642; in general medicine (CTF) 302, 553; in psychiatry (CTF) 644; in Tourette's Syndrome, 288; in toxicology (CTF) 69; in obstetrics/gynecology (CTF) 872
 Clozapine, in obstetrics/gynecology (CTF) 228
 Clotriazole, in obstetrics/gynecology (CTF) 68
 Coats, Eugene A. (author) book review, 562
 Cocchetto, David M. (coauthor) A Bibliography for Selected Pharmacokinetic Topics, 769
 Codeine Phosphate, in gastroenterology (CTF) 442
 Cohen, Marie M. (coauthor) letter, see Crogan, F. James, 791
 Colchicine, and reproductive function (DIAS Rounds) 428; in dermatology (CTF) 145; in rheumatology (CTF) 304
 Coleman, James H., III, chairman, nominating committee, ACCP, 167
 Colestipol, in cardiovascular disease (CTF) 441
 Compliance, elderly patients, 334; self-monitoring of blood pressures in hypertensive subjects, 424
 Conner, Christopher S. (author) letter, reply to comment on CTF column, 440; (coauthor) letter, authors' reply,

- 136; (coauthor) see **Snodgrass, Wayne**, 783; (editor) **Current Therapeutic Findings**, 67, 145, 227, 302, 379, 441, 553, 642, 720, 796
- Containers**, prescription, evaluation in arthritic patients, 794
- Continuing Education**, professional intervention in patient care, 415
- Contraceptives**, oral, progestogens with antiandrogenic properties, 377
- Copeland, Gary P.** (coauthor) *The Pharmacist Practitioner Training Program*, 114
- Corrections**, in CTF column, 136; *Index Nominum* correction, 789; to iv guidelines, 791; to letter on clinical practice in Riyadh, 440; to *Washington News and Comment*, Vol. 14, No. 2, 734; ACCP news, 870
- Corticosteroids**, in pediatrics (CTF) 721; in thyroid storm, 350; letter of comment, 719; proposed action in septic shock, 248; septic shock, review and analysis, 247
- Cost**, effect of clinical pharmacist on intravenous medication, 516; *Guide to Prescription Drug Costs* available, 733; impact of the doctent clinical pharmacist, 266
- Co-trimoxazole**, use in acne, 500; in infectious disease (CTF) 872
- Covinsky, Joel O.**, chairman, credentials committee, ACCP, 167; (coauthor) *A Look at the Educational Responsibilities and Cost Impact of the Doctent Clinical Pharmacist*, 266; (coauthor) see **Kelly, Kim L.**, 516
- Crabtree, Brian L.** (coauthor) letter, clarification of phenytoin kinetics, 294
- Crom, William R.** (coauthor) book review, 561
- Cromolyn**, in pulmonary disease (CTF) 146; for mastocytosis, 843; in ophthalmology (CTF) 872
- Cupit, Gary C.** (coauthor) see **Day, Robert L.**, 358
- Current Therapeutic Findings**, 67, 145, 227, 302, 379, 441, 553, 642, 720, 796
- Cyclamates**, FDA update, 305
- Cyclandelate**, in neurology (CTF) 643
- Cyclobenzaprine**, in general medicine (CTF) 67
- Cyclophosphamide**, in combination with vincristine/dactinomycin in pediatrics (CTF) 554; in oncology (CTF) 146; in rheumatology (CTF) 798; metabolite used to inhibit adriamycin microsomal metabolism (ab 10), 634; ovarian cancer, 594
- Cyproheptadine**, in endocrinology (CTF) 442
- Cytarabine**, in oncology (CTF) 228
- D**
- Dactinomycin**, in combination with vincristine/cyclophosphamide in pediatrics (CTF) 554
- Dana, William J.** (author) *Vindesine Sulfate*, 28
- Danzon**, in endocrinology (CTF) 642; in general medicine (CTF) 67
- Dapsone**, use in acne, 500
- Dasta, Joseph F.** (author) comments on septic shock article, 867
- Davis, Frank T.** (coauthor) see **Salem, Ronald B.**, 605
- Davis, Larry J.** (coauthor) see **Ogawa, Gary S.**, 158; (coauthor) *DIAS Rounds*, see **Shimomura, Sam K.**, 428; (coauthor) *DIAS Rounds*, see **Stephens, Nancy M.**, 100; (editor) *DIAS Rounds*, 99, 187, 428, 842
- Day, Robert L.** (coauthor) Task Force Report on Cautionary Statements in OTC Advertisements, 358
- Dean, Roger F.** (author) bleeding associated with concurrent warfarin and metronidazole therapy, 864
- Deferoxamine**, in hematology (CTF) 145, 872
- Deglin, Judith M.** (coauthor) case report, Sodium and Water Retention Associated with Indomethacin Therapy, 620; (coauthor) Quinidine-Induced Fever and Hepatic Dysfunction, 216
- Deiner, Carl H.** (author) letter, report on the average hospital pharmacy, 551
- Delta-9-tetrahydrocannabinol**, in oncology (CTF) 228, 443
- Department of Health and Human Services**, formerly HEW, 157
- Depression**, maprotiline, a new antidepressant, 585
- Dermatology**, OTC products containing hydrocortisone, 159
- Dermatology (CTF)**, acne 379; allopurinol, 553; amcinonide, 302; cimetidine, 796; cinnarizine, 379; colchicine, 145; dexametazone 67; fluocinonide, 553; levamisole, 67, 796; local anesthetics, 441; miconazole nitrate, 442; niacinamide, 720; nitrogen mustard, 229; propylene glycol, 796; psoriasis, 720; terbuthaline/theophylline, 379; thalidomide, 642; undecylenic acid, 796; zinc sulfate, 720; 5-fluorouracil, 871; naproxen, 871; 13-cis-retinoic acid, 871
- Desipramine**, plasma concentrations of metabolites (ab 9), 633
- DeTullio, Pam** (author) cromolyn sodium for mastocytosis (ab 843)
- Devine, Ben J.** (coauthor) letter, see **Thompson, Gregory A.**, 627
- Dexamethasone**, in septic shock, 250
- Dextranomer**, in dermatology (CTF) 67; in infectious disease (CTF) 68
- Diabetes**, effects of beta-blockers, 49; hyperglycemia induced by phenytoin (case report) 544; transplantation of insulin-producing cells, 850
- Dialysis**, increase in number of patients requiring, 814; peritoneal, decreased gentamicin half-life, 218
- Diarrhea**, in gastroenterology (CTF) 871
- DIAS Rounds**, 99, 187, 428, 842
- Diazepam**, disposition in epileptic children (ab 20), 636; in anesthesiology (CTF) 67, 553; in intravenous therapy (CTF) 442; in obstetrics/gynecology (CTF) 797; interaction with cimetidine (ab 8), 633; PPIs, 229; in psychiatry (CTF) 555; pharmacokinetics with elevated serum lipid levels, 765
- Diazoxide**, for premature labor, 758; in pediatrics (CTF) 146; in pulmonary disease (CTF) 228
- DiBona, John R.** (author) book review, 563
- Dicumarol**, interactions with phenytoin, 669
- Diet, Cambridge, FDA preapproval**, 733
- Diffusional**, in rheumatology (CTF) 381, 798
- Digoxin**, algorithm for interaction with quinidine, 57; in breast milk, 101; in obstetrics/gynecology (CTF) 643; in pregnancy, 100; in toxicology (CTF) 69; individualized method for dosing in an extended care facility, 507; toxicity with therapeutic levels (case report) 547; interaction with quinidine, 969; in cardiovascular disease (CTF) 871
- Dihydroergotamine**, in toxicology (CTF) 555
- Dihydrothachysterol**, in renal disease (CTF) 555
- Diphenoxylate**, illicit use to prevent narcotic withdrawal symptoms, 715; in gastroenterology (CTF) 442
- DiFiore, Joseph T.** (coauthor) Gentamicin Nephrotoxicity During Dosing Controlled by Gentamicin Serum Levels, 53
- Director, Kenneth** (coauthor) see **Salem, Ronald B.**, 622
- Dopamine**, in cardiovascular disease (CTF) 145
- Diuretics**, see also individual agents, potassium chloride supplementation (ab 29), 638; in general medicine (CTF) 720
- Dobutamine**, in cardiovascular disease (CTF) 871
- Doering, Paul L.** (author) book review, 559
- Dopamine**, in cardiovascular disease (CTF) 145
- Dorr, Robert T.** (coauthor) letter, see **Appelbaum, Steven J.**, 789
- Doxorubicin**, in obstetrics/gynecology (CTF) 228
- Doxycycline**, use in acne, 500
- Draize Test**, defended by FDA, 733
- Droperidol**, in alcohol-phenology (CTF) 553
- Drug Abuse**, eosinophilia with methylphenidate abuse, 189; publication (letter) 298; increase in illicit drug use, 880
- Drug History**, evaluation of ROS method (ab 32), 638
- Drug Information**, center in Spain, 263; comment (letter) 286; consumer reactions to dosing amounts, 531
- Drug Interactions**, impact of patient information on prescribing patterns, 280
- alcohol-cefoperazone (CTF) 723**
- alcohol-diazepam (CTF) 147**
- alcohol-diphenhydramine (CTF) 723**
- allopurinol-cyclophosphamide (CTF) 799**
- ampicillin-oral contraceptives (CTF) 304**
- aspirin-phenytoin (CTF) 444**
- benzodiazepines-heparin (CTF) 444**
- beta-blocking agents and anti-diabetic drugs, 46**
- bilirubin-propranolol (CTF) 799**
- blood gases-heparin (CTF) 69**
- caffeine-oral contraceptives (CTF) 723**
- carbamazepine-valproic acid (CTF) 229**
- cefoperazone-alcohol (CTF) 723**
- cheese-isoniazid (CTF) 147**
- chlorazepate-phenology (CTF) 221**
- chlorpromazine-trihexphenidyl (CTF) 444**
- cimetidine-tetracycline (CTF) 444, 874**
- cimetidine-diazepam (ab 8), 633**
- clofibrate-colestipol (CTF) 304**
- colestipol-clofibrate (CTF) 304**
- co-trimoxazole-warfarin (CTF) 229**
- cyclophosphamide-allopurinol (CTF) 799**
- diazepam-alcohol (CTF) 147**
- diazepam-cimetidine (ab 8), 633**
- diazepam-digoxin (CTF) 874**
- digoxin-diazepam (CTF) 874**
- digoxin-quinidine (CTF) 69, 723, 869**
- diphenhydramine-alcohol (CTF) 723**
- doxepin-guanethidine (CTF) 229**
- epsilon-aminocaproic acid-probenecid (CTF) 874**
- erythromycin-estriol (CTF) 874**
- erythromycin-theophylline (CTF) 645**
- estriol-erythromycin (CTF) 874**
- ethosuximide-valproic acid (CTF) 799**
- food-valproic acid (CTF) 723**
- furosemide-propranolol (CTF) 147**
- guanethidine-doxepin (CTF) 229**
- guanethidine-molindone (CTF) 147**
- heparin-benzodiazepines (CTF) 444**
- heparin-blood gases (CTF) 69**
- hydralazine-propranolol (CTF) 723**
- isoniazid-cheese (CTF) 147**
- isoniazid-tuna fish (CTF) 444**
- lidocaine-propranolol (CTF) 874**
- lithium-mazindol (CTF) 444**
- lithium-methylidopa (CTF) 444; (ab 34), 638**
- mazindol-lithium (CTF) 444**
- methylidopa-lithium (CTF) 444; (ab 34), 638**
- methylidopa-tricyclic antidepressants (CTF) 69**
- miconazole-warfarin, 93**
- molindone-guanethidine (CTF) 147**
- naloxone-nitrous oxide (CTF) 799**
- nitroprusside-skeletal muscle relaxants (CTF) 444**
- nitrous oxide-naloxone (CTF) 799**
- oral contraceptives-ampicillin (CTF) 304**
- oral contraceptives-caffeine (CTF) 723**
- oral anticoagulants-phenytoin, 669**
- oral contraceptives-tetracycline (CTF) 444**
- phenobarbital-valproic acid (CTF) 645**
- phenytoin-aspirin (CTF) 444**
- phenytoin-chloramphenicol, 221**
- phenytoin-lithium (CTF) 444**
- phenytoin-theophylline (ab 31), 638**
- phenytoin-oral anticoagulants, 669**
- phenytoin-thioridazine (CTF) 799**
- phenytoin-valproic acid (CTF) 229**
- probenecid-epsilon-aminocaproic acid (CTF) 874**
- probenecid-thiopental (CTF) 799**
- propranolol-bilirubin (CTF) 799**
- propranolol-furosemide (CTF) 147**
- propranolol-hydralazine (CTF) 723**
- propranolol-lidocaine (CTF) 874**
- quinidine-digoxin (CTF) 69, 723, 869**
- quinidine-riamycin (CTF) 69**
- riamycin-quinidine (CTF) 69**
- skeletal muscle relaxants-nitroprusside (CTF) 444**
- spironolactone-warfarin (CTF) 144**
- sulfinpyrazone-warfarin (CTF) 304**
- sulindac-warfarin (CTF) 69, 229, 304**
- sulfisoxazole-warfarin (CTF) 645**
- tetracycline-cimetidine (CTF) 444, 874**
- tetracycline-oral contraceptives (CTF) 444**
- theophylline-erythromycin (CTF) 645**
- theophylline-phenytoin (ab 31), 638**
- theophylline-troleandomycin, 527**
- thiopental-probenecid (CTF) 799**
- thioridazine-phenytoin (CTF) 799**
- tricyclic antidepressants-methylidopa (CTF) 69**
- trihexphenidyl-chlorpromazine (CTF) 444**
- troleandomycin-theophylline, 527**
- tuna fish-isoniazid (CTF) 444**
- valproic acid-carbamazepine (CTF) 229**
- valproic acid-ethosuximide (CTF) 799**
- valproic acid-food (CTF) 723**
- valproic acid-phenobarbital (CTF) 645**
- valproic acid-phenytoin (CTF) 229**
- vitamin K-warfarin (CTF) 799**
- warfarin-co-trimoxazole (CTF) 229**
- warfarin-miconazole, 93**
- warfarin-spironolactone (CTF) 444**
- warfarin-sulfinpyrazone (CTF) 304**
- warfarin-sulfisoxazole (CTF) 645**
- warfarin-sulindac (CTF) 69, 229, 304**
- warfarin-vitamin K (CTF) 799**
- Drug Interactions Update**, 46, 331
- Drug Log**, CAO criticism report, 879
- Drug Levels**, differentiating between toxic and inappropriately drawn serum levels, letter, 220; problems (letter) 718
- Drugs**, methodologies for product selection studies, 126
- Drug Therapy**, clinical significance of consultant pharmacist recommendations and the skilled nursing facility, 182; in renal disease (CTF) 873
- Duggan, H.E.** (coauthor) letter, see **McOrmond, P.**, 549
- Duran, Juan** (coauthor) see **Bonal, Joaquin**, 259
- Dyphylline**, in pulmonary disease (CTF) 798
- E**
- Editorials**
- George F. Archambault**, *The Art of Communication*, 464; *CME, GDE, and Unit-of-Use—An Update*, II, 80; *Journal Clubs and the Pharmacy Department*, 400; *The 'Man-In-The-Plant' Problem Won't Go Away*, 320; *Patient Package Inserts and the Unit-of-Use (Patient Package)—An Update*, 736; *Pharmaceutical Pedagogy: Redundancy—An Important Tool of Teaching*, 656; *Pharmacy, Whither Goest Thou? Part I*, 160; *The Three Orphans of the Drug World*, 816; *Medicine and Pharmacy—Rendezvous with Time*, 882
- William M. Heller**, *USP: The Story Behind the Cover*, 430
- Leslie Hendels**, *A Time to Abandon the Use of Iodides in the Management of Pulmonary Diseases*, 619
- Peter P. Lamy**, *Geriatrics—Gerontology: A Challenge and Opportunity for Pharmacy*, 214
- Donald C. McLeod**, *The Decline and Fall of Phenacetin*, 213; *The Patient Package Insert—Rhetoric vs. Logic*, 52
- Glen L. Stimmel**, *Clinical Pharmacy and Specialization*, 540
- Miles Weinberger** (coauthor), *A Time to Abandon the Use of Iodides in the Management of Pulmonary Diseases*, 619
- Harvey A. K. Whitney**, Jr., *Accomplishing a Goal for DICP with Specialty Panels*, 51; *The Application of Gordon Research Conferences to Pharmacy*, 710; *Clinical Team Role Models are Needed Within Pharmacy*, 134
- Education**, cephalosporin education program, 272; course in applied pharmacokinetics, 430; drug compliance and the elderly, 335; ethics and clinical pharmacy education, 537; redundancy, an important tool of teaching (ed) 656; responsibilities of the doctent clinical pharmacist, 266; specialty, 32; student assessment of teacher performance (ab 18), 635
- Egan, Dorothy** (coauthor) see **Raber, Jack**, 868
- Einarsen, Thomas R.** (author) case report, Hallucinations from Triazolam, 714; (author) Hostility Reaction to Flurazepam, 291
- Elderly**, responsible use of prescription medications, 335
- Elenbas, Julia** (author) *DIAS Rounds*, enflurane hepatotoxicity, 428; (coauthor) see **Furniss, Leesa**, 842
- Elger, Janet F.** (coauthor) see **Rapp, Robert E.**, 193, 791
- Ellenor, Gary L.** (coauthor) see **Wade, Lance C.**, 17
- Encaidine**, in cardiovascular disease (CTF) 553
- Endocarditis**, in infectious disease (CTF) 303
- Endocrinology**, (CTF) beta-blocking agents, 796; bromocriptine, 57, 227, 796; clomiphene, 227; cyproheptadine, 442; danazol, 642; glipizide, 145; insulin, 302, 442, 553, 720, 796; methimazole, 379; phenobarbital, 796; phenytoin, 642; sodium phosphate, 720; thyroid hormones, 302
- Endometrial Cancer**, estrogens, 406
- Enflurane**, hepatotoxicity (*DIAS Rounds*) 428; in anesthesiology (CTF) 227; hepatic coma, 863
- Eosinophilia**, characteristic in methylphenidate abusers, 189
- Epidemiology**, estrogens and endometrial cancer, 406; *The Dunedin Program*, geriatric screening (ab 30), 638
- Ereshefsky, Larry** (coauthor) letter, authors' reply, 138
- Eros, P. Albert** (coauthor) see **Lundin, Dorothy V.**, 335
- Errick, Jeffrey Keith** (coauthor) case report, probable erythromycin ototoxicity, 623
- Erythrocytes**, lithium, indicators of mood changes, 836
- Erythromycin**, effect on theophylline kinetics (ab 25), 637; effect on theophylline blood levels, 528; for gonococcal ophthalmia neonatorum, 59; hemodialysis, 59

hepatotoxicity (letter) 627; in infectious disease (CTF) 145, 872; oral ulceration, 217; ototoxicity (case report) 623; patient package insert study, 531; topical, efficacy study of drug and vehicle versus vehicle alone (ab 24).

637; use in acne, 500; stability in intravenous solutions, 548.

Erythromycin Estolate, proposal to remove from market, 158.

Estradiol Valerate, in obstetrics/gynecology (CTF) 797.

Estrogens, in obstetrics/gynecology (CTF) 303.

Ethanol, for premature labor, 738; in general medicine (CTF) 379.

Ethics, education, clinical pharmacy practice, 537.

Ethosuximide, pharmacokinetic calculations, 674.

Ethylene glycol, in toxicology (CTF) 644.

Etoposide, in oncology (CTF) 68.

Evans, William E. (coauthor) book review, 561; credentials committee, ACCP, 167.

Evans, Ronald P. (author) Erythromycin—Oral Ulceration, 217; (coauthor) letter, see **Lakey, Melissa**, 136; (coauthor) see **Guernsey, Brock G.**, 59.

F

Federal Drug Administration (FDA), address, **Jerome E. Goyan**, 238; changes in procedures concerning INDs, NDAs, and ANDAs, 237; enforcement report, how to obtain, 462; expiration dates, 239; hair dye, warning required, 238; infant formula recalled, 239, 1981 budget, 462; peroxide, 239; PPIs, FDA's right to decide contents, 319; recent appointments to staff, 734; regulatory proceedings, expenses paid by new pilot program, 238; status of drug efficacy study implementation, 571; unsafe and ineffective drugs removal, 513; X-rays, overuse of, 239.

Fendler, Kermit (coauthor) see **Kelly, Kim L.**, 516.

Fenofibrate, in rheumatology (CTF) 304.

Ferguson, Roger K. (coauthor) see **Zappacosta, Anthony R.**, 373.

Ferritin, and anemia of chronic renal failure, 494.

Fever, quinidine-induced, 216.

Fields, Ellen D. (author) book review, 62, 560, 564.

Finley, Rebecca S. (author) letter, comments on amphotericin-B therapy, 719.

Fleckenstein, Lawrence L., constitution and bylaws committee, ACCP, 167.

Floyd, Ronald A. (coauthor) letter, differentiating between toxic and inappropriately drawn serum drug levels, 220.

Fluocinonide, in dermatology (CTF) 553.

Fluoride, rinses and gels, OTC status recommended, 572.

5-Fluorouracil, clearance in patients with hepatic metastases (ab 1), 634; for ovarian cancer, 594; in obstetrics/gynecology (CTF) 554, 797; in oncology (CTF) 721; in dermatology (CTF) 871.

Fluorol-DA, in general medicine (CTF) 871.

Flurazepam, hostility reaction (case report) 291.

Flurbiprofen, in rheumatology (CTF) 229.

Food and Drug Law Institute, meetings held, 653, 30th annual conference, 319.

Food and Drug Law of the United States, reprints available, 79.

Food, Drug, and Cosmetic Act, amendments submitted to Congress, 571.

Formulas, infant, public hearings, 397; recall, 239; salt deficiency, 318.

Fortner, Clarence L. (coauthor) letter, see **Finley, Rebecca S.**, 719.

Foster, Thomas S., budget and finance committee, ACCP, 167; (coauthor) case report, possible hepatotoxicity with roxarsomycin—a new antibiotic related to erythromycin, 786; (coauthor) Legal and Ethical Issues in Clinical Pharmacy Research—Informed Consent, Part I, 40.

Frail, Dawn M. (author) book review, 560.

Francis, Paul (coauthor) see **Berg, Mary J.**, 636.

Franchon, Don E., honored by national library, 653.

Frazier, Donald G. (author) phenothiazine potentiation of metrizamide seizures (ab) 843.

Frederick, David S. (author) Phenazopyridine-Induced Hemolytic Anemia, 290.

Freedom of Information, statistics on request, 574.

Freeze-Thaw Treatments, iv admixtures, 353.

Furniss, Leesa (author) metolazone-furosemide synergism (ab) 842.

Furosemide, synergism with metolazone, 842.

G

Gambertoglio, John G., budget and finance committee, 167.

Gammill, George D. (coauthor) see **Murphy, John E.**, 420.

Gastroenterology (CTF), antacids, 302, 553; azathioprine, 720; bromocriptine, 553; cholelithiasis, 302; cimetidine, 67, 145, 442, 642; codeine phosphate, 442;

diphenoxylate/atropine, 442; lithium carbonate, 720; Mauds, 227; metoclopramide, 145; mono-cetamin, 720; prednisolone, 379; prednisone, 67; primum bromide, 145; prostaglandin E₂, 442; 6-mercaptopurine, 553; somatostatin, 554; sulfasalazine, 67; traveler's diarrhea, 642; ursodeoxycholic acid, 720;

antibiotic-induced diarrhea, 871; levodopa, 871; metronidazole, 871; trifluoperazine, 871;

Zollinger-Ellison syndrome, 871.

Gee, Joseph P. (coauthor) see **Jim, Lucia K.**, 371.

Geiger, Gail S. (author) letter, formulation for gentamicin syrup, 297.

General Medicine (CTF), acid-base disorders, 720; albumin, 797; alcohol, 67; amantadine, 797; bismuth subsalicylate, 302; bromocriptine, 554; clonidine, 302, 554; chlorpheniramine, 145; C₁PR, 797; cyclobenzaprine, 67; danazol, 67; diuretics, 720; ethanol, 379; histamine, 379; hydrochloric acid, 554; hydroxyethyl starch, 643;

meperidine, 643; naproxen, 442; nifedipine, 554; nitrous oxide, 227; Page's disease, 643; potassium chloride, 227; propranolol, 145; prostaglandin A, 379; somatostatin, 302; urea, 797; venereal diseases, 379; albumin, 871; Fluorol-DA 208, 871; rabies vaccine, 871; urea, 871.

Genitourinary, case report, nephrotoxicity, 53; decreased half-life during peritoneal dialysis, 218; freeze-thaw treatment study, 353; in infectious disease (CTF) 146, 380; in pediatrics (CTF) 554; syrup formulation (letter) 297.

Geriatrics, 182, 513.

Geriatrics, challenge for pharmacy (ed) 214; drug compliance study, 335; medicine brochure published, 399; method for dosing digoxin in an extended care facility, 507; The Dunedin Program, epidemiologic study (ab 30), 638; use of amantadine, (letter), 377.

Gerontology, challenge for pharmacy (ed) 214.

Gibaldi, Mido (coauthor) see **Koup, Jeffrey R.**, 327.

Gill, Mark A. (coauthor) see **Hayashi, Robert J.**, 189.

Glipizide, in endocrinology (CTF) 145.

Glucose-6-Phosphate Dehydrogenase Deficiency, with dapson therapy, 413.

Glue, in toxicology (CTF) 229.

Glycerol, intravenous therapy in Beye's Syndrome (ab 21), 636.

Glycopyrrolate, in ophthalmology (CTF) 68.

Goehrs, Homer (coauthor) see **Waller, Elaine**, 412.

Gold Salts, in pediatrics (CTF) 644.

Gonorrhea, therapy of choice (CTF) 442.

Goss, C.M.A.A. (coauthor) see **Vernon, A.J.M.**, 498.

Gordon Research Conferences, applied to pharmacy (ed) 710.

Goyan, Jerome E., excerpts of address to FDA, 238; remarks from installation ceremonies, 78.

Greenlaw, Cal Wayne (author) Liver Enzyme Elevation Associated With Total Parenteral Nutrition, 702; (coauthor) see **Rymer, William**, 780.

Grimblat, Joseph (coauthor) case report, renal tubular necrosis and liver damage, 431.

Grogan, F. James (coauthor) letter, a fortuitous medication error, 791.

Grossman, Joshua B. (author) letter, clinical judgment in cardiomyopathy case, 793; (author) letter, detection of chronic lung disease, 298; (author) Morgans-Stokes-Adams Syndrome, 56.

Guernsey, Brock G. (coauthor) letter, ophthalmic erythromycin and tetracycline for gonococcal ophthalmia neonatorum, 59.

Guidelines, Author's, 4, 84, 162, 242, 322, 402, 466, 578, 738.

Guide to Prescription Drug Costs, how to obtain, 733.

Gulick, B. (coauthor) letter, see **McOrmond, P.**, 549.

Gurwich, Ernest L. (coauthor) see **Tung, Elizabeth Chow**, 848.

H

Hackett Packet, 158.

Hahn, Deborah A. (coauthor) Hexamethylmelamine: A Review, 591.

Hair Dye, FDA warning, 238.

Hall, K. (coauthor) see **Ahsanuddin, K.**, 288.

Haller, David L. (author) The Use of Terbutaline for Premature Labor, 757.

Haloperidol, in rheumatology (CTF) 644; in psychiatry (CTF) 873.

Halothane, in anesthesiology (CTF) 227; renal tubular necrosis and liver damage, 431.

Halperin, Jerome A. (author) Equity for the Pharmacist: Recognition with Responsibility, 489; (author) From Investigation to Marketplace: Moving Drugs Through the System, 694; (author) A Policy Experiment in the Regulation of Human Drugs, 845.

Hamburger, Stephen (coauthor) see **Covinsky, Joel O.**, 266.

Hansten, Philip D. (coauthor) see **Day, Robert L.**, 358; (editor) Drug Interactions Update, 46, 331; nominating committee, 167.

Happen Dextran, in cardiovascular disease (CTF) 642.

Harbaugh, Terry (coauthor) letter, see **Floyd, Ronald A.**, 220.

Hart, Linda L. (author) DIAS Rounds, single-dose treatment for UTI, 187; (coauthor) DIAS Rounds, see **Lum, Grant**, 429; (editor) DIAS Rounds, 99, 187, 428, 542; (coauthor) see **DeTullo, Pam**, 843.

Hattersley, Paul G. (author) letter, bleeding with iv heparin, 220.

Hayashi, Robert J. (coauthor) The Characteristics of Eosinophilia in a Series of Intravenous Methylphenidate Abusers, 189.

Health, little action in Congress, 157; right to happiness, 108.

Health Care, pharmacist practitioner training program, 114.

Health Care Financing Administration (HCFA), drug payment guidelines, 77; hospice care for Medicaid patients, 317.

Health Professions, status of personnel in the U.S., 574.

Heath, Randolph (coauthor) letter, see **Ives, Timothy**, 378.

Heller, William M. (ed) USP: The Story Behind the Cover, 430.

Helling, Dennis K., programs committee, ACCP, 167; (author) Antibiotic Sensitivity of Penicillin—Resistant *Staphylococcus Aureus* in Three Midwestern Family Practice Populations, 851.

Hematology (CTF), aminocaproic acid 227; aplastic anemia, 797; deferoxamine, 145, 872; heparin, 442; intravenous iron dextran, 554; pentoxifylline, 797; lithium salts, 720; thrombotic thrombocytopenic purpura, 379; vitamin E, 720.

Hemodialysis see also **Renal Disease**; in psychiatry (CTF) 644, 721; in renal disease (CTF) 798.

Hemoperfusion, in toxicology (CTF) 69.

Hendee, Leslie (coauthor) Avoidance of Adverse Effects

During Chronic Therapy with Theophylline, 522; (ed) A Time to Abandon the Use of Iodides in the Management of Pulmonary Diseases, 619; nominating committee, 167.

Heparin, bleeding (letter) 220; clinical pharmacokinetics, 483; in cardiovascular disease (CTF) 553; in hematology (CTF) 442; in renal disease (CTF) 146.

Hepatic Disease, phenytoin hypersensitivity reaction, 252; quinidine induced, 216; use of Intralipid[®], 188; with enflurane anesthesia (DIAS Rounds) 428; with erythromycin (letter) 627; with roxarsomycin, 786.

Heroin, in toxicology (CTF) 304.

Hexamethylmelamine, review, 591; toxicity, 592.

Histamine, in general medicine (CTF) 379.

Hodgkin's Disease, in oncology (CTF) 721.

Hogan, Linda (coauthor) see **Kleinschmidt, Mark F.**, 716.

Holland, Nancy J. (coauthor) see **Blou, Robert A., Jr.**, 218.

Holloway, Donald A. (author) book review, 233.

Holmes, C.J. (coauthor) Activity of Antibiotic Admixtures Subjected to Different Freeze-Thaw Treatments, 353; (coauthor) see **Asmus, R.K.**, 284.

Hopkins, Leigh (coauthor) see **Lee, Mary**, 57.

Hopper, J. (coauthor) letter, see **McOrmond, P.**, 549.

Horn, John R. (author) book review, 563.

Hospital Pharmacy, a report, letter, 551; in Spain, 259.

Howse, C.R. (coauthor) letter, the sensitivity of a voluntary drug experience reporting system, 439.

Hughes, Larry B. (coauthor) see **Koren, James F.**, 711.

Hughes, Mary (coauthor) see **Berg, Mary J.**, 636.

Hull, J. Heyward, III (coauthor) see **Adams, Thomas R.**, 280; programs committee, ACCP, 167.

Hull, Robert Lee (author) letter, comments on thyroid storm article, 790.

Hunt, Richard B. (coauthor) case report, see **Rietscha, William J.**, 436.

Huntington's Disease, research centers established, 814.

Hydralazine, in cardiovascular disease (CTF) 553, 642.

Hydronephrosis, in pulmonary disease (CTF) 228; pharmacokinetics redefined (ab 19), 638.

Hydrocarbons, in toxicology (CTF) 644.

Hydrochloric acid, in general medicine (CTF) 554.

Hydrochlorothiazide, potassium chloride supplementation (ab 29), 638.

Hydrocortisone, in OTC products, 159; in pediatrics (CTF) 554; USP retains name, Feb-ctr 1.

Hydroxyethyl Starch, in general medicine (CTF) 643.

L-S-Hydroxytryptophan, in neurology (CTF) 797.

25-Hydroxyvitamin D₃, in renal disease (CTF) 555.

Hyperalimentation see also **Total Parenteral Nutrition**; in nutrition (CTF) 303; in oncology (CTF) 380, 643; in psychiatry (CTF) 555.

Hypertension, abrupt discontinuation of captopril (ab 33), 638; impact of the clinical pharmacist (ab 13), 634; malignant, use of captopril, case report, 373; self-monitoring and its effects on patient compliance, 424; nadolol, 826.

Hypoglycemia, cardiovascular effects, 48; signs and symptoms, 48.

Hypokalemia, with amphotericin B, 178.

Hypoprothrombinemia, with cefamandole, 780.

Hypotension, in hemodialysis patients following timolol (ab 1), 632.

Hyrcin-Flaska, Lisa (coauthor) see **Errick, Jeffrey Keith**, 623.

Hysterectomy, vaginal, comparison of ampicillin, cephalothin and cephradine (ab 26), 637.

I

Ibuprofen, in obstetrics/gynecology (CTF) 442; in oncology (CTF) 303; renal side effects (letter) 297; in rheumatology (CTF) 873.

Imipramine, in urology (CTF) 644; plasma concentrations in metabolites (ab 9) 633.

Imoto, Ronald M. (author) DIAS Rounds, benzodiazepine withdrawal reaction, 187; (author) DIAS Rounds, digoxin, propranolol, quinidine, and pregnancy, 100.

Indian Health Service, primary health care by pharmacists, 114.

Indomethacin, acute renal failure, case report, 711; in neurology (CTF) 228; in pediatrics (CTF) 380; in rheumatology (CTF) 644; in urology (CTF) 555; sodium and water retention (case report) 620.

Infectious Disease, (CTF) amikacin, 68, 643; amoxicillin, 145, 442, 797; amphotericin B, 720; amphotericin B/lucylosine, 227; antibiotics, 379, 442; bacitracin, 720; cefaclor, 145, 643; cefadroxil, 379;

cefamandole/tobramycin, 554; cefazolin, 379, 442; cefotaxime, 303; cefuroxime, 797; cephalothin, 380; cephradine, 68; dextranomer, 68; endocarditis, 303; erythromycin, 145; flucytosine/amphotericin B, 227; gentamicin, 146, 380; gonorrhea, 442; ketoconazole, 227; mebendazole, 146; metronidazole, 68, 146, 303, 380, 721; miconazole, 303; nocardiosis, 797; pelvic inflammatory disease, 554; povidone-iodine, 227; procaine penicillin G, 554; rifampin, 380; sulfamethoxazole-trimethoprim, 354; trimethoprim, 721, 797; tobramycin/cefamandole, 554; trimethoprim/sulfamethoxazole, 228; vancomycin, 442; cefazolin/tobramycin, 872; co-trimoxazole, 872; erythromycin, 872; metronidazole, 872; piperacillin, 872.

Informed Consent, final step in clinical pharmacy research, 122.

Inotropic Agents, in cardiovascular disease (CTF) 642.

Inoue, Fumio (author) letter, author's reply, 139.

Insomnia, national program for sleep disorders, 157.

Insulin, in endocrinology (CTF) 302, 442, 553, 720, 796.

Intermittent Infusion Systems, in intravenous therapy (CTF) 67.

International Federation of Pharmacy, 40th international congress and 28th general assembly, 398.

Intralipid[®], in hepatic dysfunction, 188.

Intraocular Lenses, FDA update, 396.

Intrathecal, amphotericin B administration, 180.

Intravenous Drugs, guidelines for administration, update, 193

Intravenous Solutions, crystallization in normal saline, 605; freeze-thaw technique for antibiotic admixtures, 353; freeze-microwave thaw technique, 284; impact of clinical pharmacist activity, 517; determining final dextrose concentrations, 820

Intravenous Therapy, national survey, 792

Intravenous Therapy (CTF), antibiotics, 146; buprenorphine, 643; carmustine, 643; cimetidine, 380; diazepam, 442; intermittent infusion systems, 67; iron dextran, 303

Investigational Drug Information, 28

Investigational New Drugs, applying for license, 158; changes in procedures, 237

Iodides, abundance use for pulmonary diseases (editorial) 619; in thyroid storm, 349

Iodocholesterol, USP retains name, Fe-ctr 1

Ipecac Syrup, in toxicology (CTF) 644

Iron, in nutrition (CTF) 380, in toxicology (CTF) 798; fortification of selected foods recommended, 879

Iron Dextran, in hematology (CTF) 554; in intravenous therapy (CTF) 303

Ischemia Transient Cerebral, in neurology (CTF) 721

Isobutyl Nitrite, in toxicology (CTF) 722

Isotiazid, in toxicology (CTF) 381

Isoproterenol, beta receptor sensitivity studies in chronic renal failure (ab 1), 632; in pulmonary disease (CTF) 228

Ives, Timothy J. (author) case report, illicit use of diphenoxylate hydrochloride to prevent narcotic withdrawal symptoms, 715; (coauthor) letter, amitriptyline-induced tonic-clonic seizures in the mentally retarded, 378

J

Jackson, Eric A. (editor) New Drug Evaluations, 11, 86, 169, 477, 585, 825

Jackson, M. (coauthor) letter, see Adams, P.C., 294

Jim, Lucia K. (coauthor) case report, acetazolamide-induced metabolic acidosis, 371

Jinks, Martin J. (author) War Stories From The Palouse, 698

Johnson, Kirk S. (coauthor) letter, see Sawyer, William T., 719

Joint Commission on Accreditation of Hospitals, recognition given to dentistry, 157

Jones, Mark E. (coauthor) see Helling, Dennis K., 851

Jusko, William J., programs committee, ACCP, 167

K

Kanouse, David E. (coauthor) see Morris, Louis A., 531

Kaul, Alan E. (coauthor) see King, William, 686; (author) terbutaline sulfate overdose, 866

Kayser, Steven R. (author) book review, 449

Kelly, Kim L., American College of Clinical Pharmacy, 8; (author) letter, comments on establishment of the ACCP, 790; (author) letter, response to American College of Clinical Pharmacy: why? 293; (coauthor) The Impact of Clinical Pharmacist Activity on Intravenous Fluid and Medication Administration, 516; (author) letter, ACCP acknowledges funds, 868

Kelly, William N. (coauthor) see Berg, Mary J., 836

Kennedy, Dianne L. Crosby (author) Estrogens and Endometrial Cancer, 406

Kern, Jack W. (coauthor) see Hayashi, Robert J., 189

Ketoconazole, in infectious disease (CTF) 227

Kineaid, B. Samuel (coauthor) see Koren, James F., 252

King, William (coauthor) Phenytoin Dosage with a Program mable Calculator, 686

Kirking, Duane M. (coauthor) see Schondelmeyer, Stephen W., 30

Kleinman, Larry M. (coeditor) Investigational Drug Information, 28

Kleinschmidt, Mark F. (coauthor) case report, An Allergic Reaction to a Vitamin B₁₂ Preparation, 716

Krupp, Deanne E. (coauthor) Method for Post-Marketing Screening of Adverse Reactions to Drugs, 23

Kodack, Michael (coauthor) see Tung, Elizabeth Chow, 848

Koren, James E. (coauthor) case report, Indomethacin-Induced Acute Renal Failure: Report of a Case and Review of the Literature, 711; (coauthor) Phenytoin Hypersensitivity Reaction: Hepatic Necrosis, 252

Kostenbauder, Harry B. (coauthor) see Berg, Mary J., 836

Koup, Jeffrey R. (coauthor) Some Comments on the Evaluation of Bioavailability Data, 327

Kowalski, M. (coauthor) see Ahsanuddin, K., 228

Kowlenko, Michael (author) letter, an additional comment on morphine iv infusion, 296

Kristein, David J. (coauthor) see Miller, Douglas A., 182

Kroboth, Patricia Dowley (coauthor) letter, hepatotoxicity and erythromycin, 827

Kundsin, R.B. (coauthor) see Ausman, R.K., 284; (coauthor) see Holmes, C.J., 353

Kurdi, William J. (author) letter, iv therapy national survey, 792

L

Labeling, OTC drugs, cautionary statements, 358; patient information, FDA proposal, 609

Labetalol, pharmacokinetics, 746

Lacombe, Pablo Salva (author) letter, contraceptives containing progestogens with antiandrogenic properties, 377

Laetrelle, FDA wins case, 397; National Cancer Institute begins tests with patients, 653; update, 397

Lakey, Melissa (coauthor) letter, reserpine and breast cancer, 136

Lamy, Peter P. (author) Drug Interactions and the Elderly—A New Perspective, 513

Geriatrics—Gerontology, A Challenge and Opportunity for Pharmacy (ed) 214; (editor) Geriatrics, 182, 513

Lantz, Robert K. (coauthor) see Berg, Mary J., 836

Latta, Robert (coauthor) see Berg, Mary J., 836

LaVerde, Salvatore (coauthor) letter, see Torre, Michael S., 222

Leclithin, in psychiatry (CTF) 146

Lee, Edwin W. (author) hepatic coma following enflurane anesthesia, 863

Lee, Mary (coauthor) letter, algorithm for digoxin-quinidine interaction, 57; (coauthor) see Schwartz, Rowena, 867

Leech, Thomas (coauthor) letter, see Floyd, Ronald A., 220

LeFevre, Joseph (coauthor) see Miederhoff, Patrick A., 537

Lesar, Timothy (author) case report, toxic lidocaine levels with diminished cardiac output and prolonged infusions, 435

Letters to the Editor, acetazolamide metabolic acidosis, 795; activity of amphotericin B after filtration, 719; additional problems associated with serum drug levels, 718; algorithm for digoxin-quinidine interaction, 57; allopurinol absorption from rectal suppositories, 789; an additional comment on morphine iv infusion, 296; American College of Clinical Pharmacy: individual prestige vs professional needs, 293; American College of Clinical Pharmacy: why? 293; Dr. Kelly's response, 293; amitriptyline-induced tonic-clonic seizures in the mentally retarded, 378; article on corticosteroid therapy, 719; bleeding with iv heparin, 220; author's reply, 220; clarification of phenytoin kinetics, 294; clinical judgment in cardiomyopathy case, 733; comments on amphotericin-B therapy, 719; comments on antipsychotic drugs, 138; author's reply, 138; comments on benzodiazepine reaction, 723; comment on CTF column, author's reply, 440; comments on drug information sources, author's reply, 296; comments on editorial, pharmacy, whether guest thou? 7, 628; comments on formation of ACCP, 790; comments on lithium article, 137; author's reply, 138; comments on thyroid storm article, 790; confusing abbreviations, 552; contraceptives containing progestogens with antiandrogenic properties, 377; correction in CTF column, authors' reply, 136; correction on tetracycline, 628; correction to article on e.c. aspirin bioavailability, 628; comments on iv guidelines, author's reply, 791; detection of chronic lung disease, 298; differentiating between toxic and inappropriately drawn serum drug levels, 220; drug abuse publication, 298; evaluation of child-resistant prescription containers utilized by arthritic patients, 794; formulation for gentamicin syrup, 297; fortuitous medication error, 791; funds transferred to ACCP, 627, 868; hemodialysis of erythromycin, 549; hemolytic effect of benzyl alcohol, 549; hepatotoxicity and erythromycin, 627; ibuprofen: renal side effects, 297; Index Nominum correction, 789; iv therapy national survey, 782; journals club comment, 440; lorazepam withdrawal, 628; ophthalmic erythromycin and tetracycline for gonococcal ophthalmia neonatorum, 59; the overzealous student syndrome, 221; plan following iv cimetidine, 294; pharmacy service to OR/NR nursing staff, 222; phenytoin—chloramphenicol interaction, 221; report on the average hospital pharmacy, 351; reserpine and breast cancer, 136; the sensitivity of a voluntary drug experience reporting system, 439; use of amantadine in the elderly, 377; comments on septic shock article, 867; comments on metoclopramide review, 867; authors' reply, 868; comments on accedes, 868; comments on digoxin toxicity, 868; author's reply, 869; digoxin-quinidine interaction, 869; ACCP news correction, 870; simple computational formulas to determine D50W needed to adjust the final dextrose concentrations in intravenous solutions, 870

Levanisole, in dermatology (CTF) 67, 796; in rheumatology (CTF) 443

Levarterenol, in cardiovascular disease (CTF) 379

Levodopa, in gastroenterology (CTF) 871

Levodopa/carbidopa, in psychiatry (CTF) 303

Levitus, Zigmund (coauthor) case report, see Grinblat, Joseph, 431

Lidocaine, diminished cardiac output and prolonged infusion (case report) 435; in anesthesiology (CTF) 379, 796; in cardiovascular disease (CTF) 796, 871; treatment of seizures (case report) 436; pharmacokinetics in liver disease (ab 27), 637; two-compartment model for determining optimal sampling times (ab 7), 633

Linden, C.V. (coauthor) letter, see Howse, C.R., 439

Lipids, effect on diazepam blood levels, 765

Literature, 61, 232, 299, 382, 448, 559

Lithium, in gastroenterology (CTF) 720; in hematology (CTF) 720; in pediatrics (CTF) 644; in psychiatry (CTF) 68, 304; in thyroid storm, 349; interaction with methyldopa (ab 34), 638; kinetics in single daily dosing (ab 22), 636; toxicity, ataxia as the primary symptom, 622; erythrocyte levels as indicators of mood changes, 836

Liver, enzymes elevated with total parenteral nutrition, 702

Liver Disease, clearance of 5-fluorouracil in patients with hepatic metastases (ab 11), 634; drug disposition (ab 27), 637; with low dose acetaminophen and halothane anesthesia, 431; with total parenteral nutrition, 702; hepatic coma with enflurane, 863

Longecker, Stephen M. (author) letter, correction in CTF column, 136

Loperamide, in toxicology (CTF) 722

Lopes, Carlos A. (coauthor) see Weiner, Bruce, 831

Lorazepam, in anesthesiology (CTF) 145; in neurology (CTF) 68; withdrawal reaction, 187, (letter) 628

Loughner, John E. (author) acquired acute hemolytic anemia secondary to phenazopyridine, 861

Loxapine, in psychiatry (CTF) 381, 798

LSD, for phantom limb pain, 100

Lucarotti, Richard L. (coauthor) see Miller, Douglas A., 182

Ludden, Thomas M., programs committee, ACCP, 167

Lauffer, Carl H. (coauthor) letter, activity of amphotericin B after filtration, 719

Lum, Grant (coauthor) DIAS Rounds, pregnancy tests, 429

Lundin, Dorothy V. (author) Education of Independent Elderly in the Responsible Use of Prescription Medications, 335

Lung Disease, detection (letter) 298

Lyon, Lynn W. (coauthor) see Taylor, Jerry A., 669

Lysine Acetylsalicylate, in anesthesiology (CTF) 796

M

Maaslos, in gastroenterology (CTF) 227

MacKichan, Janis J. (author) book review, 385

Maddux, Michael S. (coauthor) Review of Complications of Amphotericin-B Therapy: Recommendations for Prevention and Management, 177

Magnesium Sulfate, for premature labor, 758

Majhanovich, John J. (coauthor) see Helling, Dennis K., 851

Mastocytosis, use of cromolyn, 843

Mannitol, prevents the toxicity to the kidney by amphotericin B, 178

Manufacturing, man-in-the-plant, update, 573

Marikar, adverse reactions, 588; new drug evaluation, 585; pharmacokinetics, 585; toxicity, 587

Mar, Dexter D. (author) letter, ibuprofen: renal side effects, 297

Marhuana, in ophthalmology (CTF) 643

Marketing, of drugs, pharmaceutical regulations, 694

Massad, Susan (coauthor) see Helling, Dennis K., 851

Maudlin, Robert K. (author) book review, 448

Mayersohn, Michael (coauthor) letter, see Appelbaum, Steven J., 789

Maynard, Susan M. (coauthor) see Bickett, William J., II, 103

McCart, Gary M. (author) DIAS Rounds, Treatment of phantom limb pain, 99

McCulloch, A.J. (coauthor) letter, see Adams, P.C., 294

McKercher, Patrick L. (coauthor) see Miller, Douglas A., 182

McLeod, Donald C., budget and finance committee, ACCP, 167; The Decline and Fall of Phenacetin (ed), 213; The Patient Package Insert—Rhetoric vs. Logic (ed), 52

McMorand, P. (coauthor) letter, hemolytic effect of benzyl alcohol, 549

McSweeney, Gail W. (coauthor) see Sohn, Catherine Ann, 272

Mebedazole, in infectious disease (CTF) 146

Medicaid, verification procedures proposed by HEW, 239

Medical Device, 1980 update conference, 814; procedure standards, 813; rules for protection, 397

Medicare, increase in hospital costs, 77; payment responsibilities, 77

Medicare-Medicaid, HEW's new sanctions to curb abuse, 461; new HCA office, 461

Medroxyprogesterone, in obstetrics/gynecology (CTF) 228; in toxicology (CTF) 380; use as contraceptive, 317

Meisel, Steven (author) digoxin-quinidine interaction, 869

Melloh, Joanne (coauthor) see Lundin, Dorothy V., 335

Melphalan, in oncology (CTF) 228; ovarian cancer, 594

Meperidine, in general medicine (CTF) 643

Mepivacaine, in neurology (CTF) 442

6-Mercaptopurine, in gastroenterology (CTF) 553

Mescaline, for phantom limb pain, 100

Mesoridazine, paralytic ileus, case report, 17

Methadone, interference with pregnancy tests (DIAS Rounds) 429

Methanol, in toxicology (CTF) 229

Methicillin, stability in intravenous solutions, 848

Methimazole, in endocrinology (CTF) 379; in thyroid storm, 347

M₂-ionine, adsorption by charcoal (ab 15), 635; USP monograph, FE-ctr 4

Methodology, for drug product selection studies, 126

Methotrexate, in oncology (CTF) 443; lung cancer, 595

Methyldopa, interaction with lithium (ab 34), 638

Methylphenidate, eosinophilia with abuse, 189

Methylprednisolone, in pulmonary disease (CTF) 443, 721; in renal disease (CTF) 555; in septic shock, 248; in neurology (CTF) 872

Metoclopramide, adverse reactions, 174; in anesthesiology (CTF) 302; in gastroenterology (CTF) 145; in toxicology (CTF) 722; new drug evaluations, 169; pharmacokinetics, 172; toxicity, 172

Metolazone, synergism with furosemide, 842

Metoprolol, in cardiovascular disease (CTF) 227, 553; in pediatrics (CTF) 721; pharmacokinetics, 746; in neurology (CTF) 872

Metricridazine, seizures potentiated by phenothiazines, 843

Metronidazole, in infectious disease (CTF) 146, 720, 872; bleeding with warfarin, 864; in gastroenterology (CTF) 871

Mianserin, in psychiatry (CTF) 381

Michelson, Paul A. (coauthor) letter, see Schneiweiss, Fred, 795

Miconazole, adverse reactions, 92; cost, 94; in dermatology (CTF) 442; in infectious disease (CTF) 303; in obstetrics/gynecology (CTF) 554; new drug evaluation, 86; pharmacokinetics, 87

Microwave, thaw technique for intravenous solutions, 284

Miederhoff, Patrick A. (coauthor) Ethics Education for Clinical Pharmacy Practice, 537

Milewski, Bob (author) letter, author's reply, 220

Miller, Arlene C. (author) book review, 386

Miller, Douglas A. (coauthor) Perceived Clinical Significance of Consultant Pharmacist Recommendations in the Skilled Nursing Facility, 182

Miller, William A., credentials committee, ACCP, 167

Minaxolone, in anesthesiology (CTF) 553

Minocycline, adverse reactions, 490; evaluation, 477; in cardiovascular disease (CTF) 379; pharmacokinetics, 478
Mirahadi, Mike K. (coauthor) Long-Term Nandrolone and Testosterone Administration in Hemodialysis Patients, 493
Misbranding, case law, 611
Mitomycin C, lung cancer, 595; in oncology (CTF) 872; in urology (CTF) 873
Miyao, Theresa E. (coauthor) see **Hayashi, Robert J.**, 159
Modified Snake Venom, in neurology (CTF) 643
Molsidomine, in cardiovascular disease (CTF) 227
Mono-naloxone, in gastroenterology (CTF) 720
Moore, Richard L. (author) Continuing Education for the Improvement of Professional Intervention in Patient Care, 415
Morgan, Patricia K. (author) letter, correction to iv guidelines, 791
Morphine, in anesthesiology (CTF) 642; iv infusion (letter) 296
Morris, Louis A. (coauthor) Consumer Reactions to Differing Amounts of Written Drug Information, 531
Muniz, Carlos E. (coauthor) see **Salem, Ronald B.**, 622
Murakami, Kathryn E. (editor) Current Therapeutic Findings, 302
Murphy, Kelly J. (editor) Current Therapeutic Findings, 145; (coauthor) letter, authors' reply, 136
Murphy, Joanne (coauthor) see **Deplin, Judith M.**, 620
Murphy, John E. (coauthor) letter, see **Crabtree, Brian L.**, 294; (coauthor) A Novel, Experimental Course in Applied Pharmacokinetics, 429
Murray, William J. (coauthor) see **Adams, Thomas R.**, 250
Mutnick, Alan H. (coauthor) Clinical Pharmacist Intervention in an Extended Care Facility, 507
Myocardial Depressant Factor, in septic shock, 245
Myopia, corrective surgery, public warned, 653

N

Nadolol, in cardiovascular disease (CTF) 145, 302, 796; pharmacokinetics, 746, 826; new drug evaluation, 825
Nalidixic acid, in toxicology (CTF) 147
Naloxone, in toxicology (CTF) 147, 443
Nandrolone, long-term use in hemodialysis patients, 493
Naproxen, in general medicine (CTF) 442; in neurology (CTF) 554; in pediatrics (CTF) 68; in dermatology (CTF) 571
National Health Service Corps, scholarships awarded, 461
Nefopam, in general medicine (CTF) 554
Negativism, in anesthesiology (CTF) 67
Nephrotoxicity, gentamicin in, 53
Neuroblastoma, in oncology (CTF) 554
Neurology (CTF) acetaminophen, 721; acetaminophen/butorphanol, 228; acetazolamide, 797; allopurinol, 68; aminocaproic acid, 797; amitriptyline, 380; aspirin, 303; barbiturates, 68, 554; bromocriptine, 643; butorphanol/acetaminophen, 228; chlorpromazine, 721; choline, 380; chymopapsin, 643; cimetidine, 303; clonazepam, 303; cyclobenzaprine, 643; L-5-hydroxytryptophan/carbidopa, 797; indomethacin, 228; lorazepam, 68; meperidine, 442; modified snake venom, 643; naproxen, 554; penicillin, 554; phenytoin, 228, 380, 442; physostigmine, 303; propranolol, 68; transaminic acid, 446; transient cerebral ischemia, 721; valproic acid, 442; alcohol, 872; methylprednisolone, 872; metoprolol, 572
New Drug Evaluations, 11, 86, 169, 477, 585, 825
Niacinamide, in dermatology (CTF) 720
Nifedipine, in cardiovascular disease (CTF) 642
Nitrogen Mustard, in dermatology (CTF) 227; lung cancer, 595
Nitroglycerin, in cardiovascular disease (CTF) 553, 871; in toxicology (CTF) 798
Nitroprusside Sodium, in cardiovascular disease (CTF) 720
Nitrosamines, update, 315
Nitrous Oxide, in general medicine (CTF) 227
Nocardiosis, in infectious disease (CTF) 797
Nonsteroidal Antiinflammatory Drugs, in rheumatology (CTF) 644
Norethisterone, in oncology (CTF) 798
Novak, Allen F. (author) letter, drug abuse publication, 298
Nuclear testing, health effects, 381
Nuremberg Code, research methodology, 41
Nurse-practitioner, impact on control of hypertension (ab) 13, 634
Nursing, drug compliance study, 335; pharmacy inservice to OR/IR staff, letter, 222
Nutrition (CTF), hyperalimentation, 303; iron, 380; oral contraceptives, 721; protein, 146; protein diet, 380; riboflavin, 68; vitamin B12, 797; vitamin E, 303; vitamins, 442; zinc, 303; safflower oil, 872
Nystatin, in obstetrics/gynecology (CTF) 68

O

Obstetrics, use of terbutaline for premature labor, 757
Obstetrics/Gynecology (CTF), aminophylline, 68; antithyroid drugs, 146; bromocriptine, 721; carboprost tromethamine, 303; cefamandole, 303; cefazolin, 643; cimetidine, 303; clonazepam, 797; clotrimazole, 68; diazepam, 797; digoxin, 643; doxorubicin, 228; estradiol valerate, 797; estrogens, 303; 5-fluorouracil, 554, 797; ibuprofen, 442; iron, 442; medroxyprogesterone, 228; miconazole nitrate, 554; nystatin, 68; OTC diuretic, 228; povidone-iodine, 721; propranolol, 146; prostaglandin E₂, 146; prostaglandin F_{2α}, 380; reboxin, 380; ritodrine, 797; teratogenicity, 228; warfarin, 303; bromocriptine, 872; clonidine, 872; prostaglandin E₂, 872; sulfadiazine, 872; nalproic acid, 872
Ocular Therapy, in ophthalmology (CTF) 554
Oderda, Gary M., chairman, constitution and bylaws committee, ACCP, 167

Ogawa, Gary S. (coauthor) DIAS Rounds, Intralipid® in hepatic dysfunction, 188
Ogbuokiri, Justina E. (author) Self-Monitoring of Blood Pressures in Hypertensive Subjects and its Effects on Patient Compliance, 424
Olin, Bernie R. (coauthor) see **Niederhoff, Patrick A.**, 537
Oncology (CTF), BCG vaccine, 303; BCNU, 303; bromocriptine, 68; bromocriptine mixture, 554; cimetidine, 303; cisplatin, 303, 554, 643, 798; cyclophosphamide, 146; cytarabine, 228; delta-9-tetrahydrocannabinol, 228, 443; etoposide, 68, 5-fluorouracil, 721; Hodgkins Disease, 721; hyperalimentation, 380, 643; ibuprofen, 303; medroxyprogesterone acetate, 380; melphalan, 228; methotrexate, 443; neuroblastoma, 554; norethisterone, 798; prostatic adenocarcinoma, 643; superficial bladder cancer, 721; tamoxifen, 68, 643; mitomycin C, 872; squamous cell carcinoma, 872
O'Neill, Robert T. (coauthor) see **Knapp, Deanne E.**, 23
Ophthalmology, OTC products, FDA recommendations, 572
Ophthalmology (CTF), alcohol, 443; cefuroxime, 146; chloral hydrate, 643; chlorpheniramine, 146; glycopyrrate, 68; marbutha, 643; ocular therapy, 554; tetracyclines, 146; thiazinadiazole, 380; timolol, 228, 643; trifluoride, 798; vitamin A, 443; cromolyn sodium, 572; oxymetazoline, 573
Oral Contraceptives, in nutrition (CTF) 721
Over-the-Counter Drugs, FDA recommendation on "Category III" drugs, 79; mandatory expiration dates, 239; removal of unsafe or ineffective drugs by FDA, 813; diuretics in obstetrics/gynecology (CTF) 228; task force report on cautionary statements, 358
Osmic Acid, in rheumatology (CTF) 443
Otitis Media, in pediatrics (CTF) 580
Ototoxicity, erythromycin (case report) 623
Oxacillin Sodium, freeze-thaw treatment study, 353
Oxprenilol, pharmacokinetics, 746
Oxtriphylline, effect on blood glucose, 546
Oxymetazoline, in ophthalmology (CTF) 573

P

Paget's Disease, in general medicine (CTF) 643
Pakes, Gary E. (author) letter, the overzealous student syndrome, 221
Panels, specialty, for DICP, 51
Paralytic Ileus, induced by mesoridazine and benzotropine mesylate, case reports, 17
Parasetamol, in toxicology (CTF) 304, 722
Parker, Chester L. (coauthor) see **Foster, Thomas S.**, 786
Fathak, Dev S. (editor) Research Methodology, 40, 122; (coauthor) Some Observations on Research Methodologies Used in Drug Product Selection Studies, 126
Patient Education, prescription medications and the elderly, 335; self-monitoring of blood pressures in hypertensive patients, 424
Patient Package Inserts, comment, 491; comments by Jere Goyan, June ctr-2; consumer reactions to amount of information, 531; freedom of speech and labeling, 609; editorial, 52
Pediatrics (CTF), pharmacokinetics of pentobarbital (ab) 6, 633; theophylline toxicity, 525; aminophylline 721, 798; anitriptyline, 228; antibiotics, 643; aspirin, 146, 721; bacterial vaccines, 443; bethanechol, 443; breast milk excretion, 380; caprolactam, 68; cefaclor, 721; cephradine, 554; chloramphenicol, 644; cholestyramine, 68; cimetidine, 443; corticosteroids, 721; diazoxide, 146; gentamicin, 554; gold salts, 644; hydrocortisone, 554; hydroxyzine, 554; indomethacin, 380; lithium, 644; metoprolol, 721; naproxen, 68; otitis media, 380; phenobarbital, 146; prednisone, 798; prostaglandin synthetase inhibitors, 443; somatostatin, 380; spectinomycin, 554; strychnine, 644; sulfasalazine, 443; terbutaline, 228; testosterone, 380; theophylline, 380, 873; trimethoprim/sulfamethoxazole, 380, 721; valproic acid, 380, 389; vincristine/dactinomycin/cyclophosphamide, 554; vitamin E, 228
Pelvic Inflammatory Disease, in infectious disease (CTF) 554
Penicillin, in neurology (CTF) 554
Penbutolol, effect on blood glucose, 47; pharmacokinetics, 746
Penicillamine, in rheumatology (CTF) 146
Penicillin G Potassium, freeze-thaw treatment study, 353; resistant *S. aureus* in family practice populations, 551
Pennyroyal Oil, in toxicology (CTF) 229
Pentamethylmelamine, new anticancer agent, 596
Pentobarbital, pharmacokinetics in brain injured children (ab) 6, 633; treatment of withdrawal reactions, 187
Pentoxifylline, in hematology (CTF) 797
Peroxide, mouth injuries, 239
Perrier, Donald (coauthor) letter, see **Appelbaum, Steven J.**, 789
Peterson, Robert G. (coauthor) see **Snodgrass, Wayne**, 783
Phantom Limb Pain, (DIAS Rounds), 100; treatment with carbamazepine, 100; treatment with hypotonic saline, 100; treatment with LSD, 100; treatment with mescaline, 100; treatment with propranolol, 100
PharmaCE Test Questions, 75, 155, 235, 315, 387, 457, 568, 651, 731, 811, 877
Pharmacist, consultant, clinical significance in the skilled nursing facility, 182
Pharmacist, Docent, education responsibilities and cost impact, 266
Pharmacist Practitioner Training Program, 114
Pharmacokinetics, amphotericin B, 177; antiepileptic drug calculations, 674; applied, a novel experimental course, 420; aspirin, 106; beta-adrenergic blocking agents, 746; bibliography for selected topics, 769; bioavailability of propranolol with nasal administration (ab) 12, 636; cinocin (ab) 3, 632; clearance of 5-fluorouracil in

patients with hepatic metastases (ab) 11, 634; diazepam and elevated serum lipid levels, 765; digoxin dosing, 509; disposition of diazepam (ab) 20, 636; erythromycin's effect on theophylline (ab) 23, 637; gentamicin, peritoneal dialysis, 218; heparin, 483; hydralazine (ab) 19, 636; lithium, single daily dosing (ab) 22, 636; liver disease (ab) 27, 637; maprotiline, 586; metoclopramide, 172; miconazole, 87; minoxidil, 478; optical sampling times (ab) 7, 633; phenytoin (letter) 294; phenytoin, dosage with a programmable calculator, 686; plasma concentrations of metabolites of imipramine and desipramine (ab) 9, 633; protein binding of desipramine (ab) 17, 635; renal clearance of cispation in children (ab) 5, 632; simple technique for predicting steady-state serum drug concentrations (ab) 2, 632; trichloromethazine in hypertensive patients (ab) 28, 637; nadolol, 826
Pharmacy, Clinical, cost impact of the decent clinical pharmacist, 266; credentialing, 664; trends in Spain, 259; impact on control of hypertension (ab) 13, 634
Pharmacy Education, no—B.S. Pharm. D. degree, 37; overzealous student, letter, 221; pharmacist practitioner training program, 114
Pharmacy Practice, clinical, ethics education, 537; clinical pharmacist impact on intravenous fluid and medication administration, 516; clinical pharmacist intervention in an extended care facility, 507; clinical pharmacy and specialization (ed) 540; equity for the pharmacist, 489; inservice to OR/IR nursing staff, letter, 222; iv admixtures, different freeze-thaw treatments, 353; Memorial Hospital Medical Center, development of pharmacy service program, 599; patient information labeling, 609
Pharmacist Technologists, part of pharmacy team (ed), 134
PharmAlert, drug abuse publication (letter) 298
Phenacetin, editorial, 213
Phenazopyridine, hemolytic anemia (case report) 290, 861
Phenyldine, in toxicology (CTF) 304
Phenobarbital, in endocrinology (CTF) 796; in pediatrics (CTF) 146; pharmacokinetic calculations, 674
Phenothiazines, interference with pregnancy tests (DIAS Rounds) 429; potentiation of metrizamide seizures, 843
Phenoxymethylamine, in urology (CTF) 722
Phenprocoumon, effect on phenytoin, 672
Phenytoin, capsules, separate USP monographs, June ctr-1; clarification of kinetics (letter) 294; dosage with a programmable calculator, 686; hypersensitivity reaction, hepatic necrosis, 252; in endocrinology (CTF) 642; in neurology (CTF) 228, 380, 442; induced hyperglycemia (case report) 544; interaction with chloramphenicol, letter, 221; interaction with oral anticoagulants, 669; interaction with theophylline (ab) 31, 632; investigation of the crystallization in normal saline, 605; pharmacokinetic calculations, 674; in renal disease (CTF) 873
Physician, prescribing patterns, impact of patient—specific drug interaction information, 250
Physostigmine, in neurology (CTF) 303
Pickett, George, rights and privileges, 108
Piccoro, John J., Jr. (coauthor) see **Blouin, Robert A., Jr.**, 218
Pietrusko, Robert G. (author) book review, 62, 448
Pindolol, effect on blood glucose, 47; pharmacokinetics, 746
Piperacillin, in infectious disease (CTF) 872
Pneumococcal Vaccine, in rheumatology (CTF) 229
Pneumonia, pneumococcal, impact of the decent clinical pharmacist, 268
Poison Control Centers, National Clearinghouse for, report, 579
Folk, Ronald E., nominating committee, 167
Folk, Kathleen (coauthor) see **Deplin, Judith M.**, 216
Polychlorinated Biphenyl (PCB), contamination of chicken and eggs, 79
Polycondritis, use of dapsone, 412
Porowski, Stephen J. (author) book review, 560
Potassium Chloride, in general medicine (CTF) 227; need, effectiveness, safety, and compliance in diuretic treated patients (ab) 29, 638
Povidone-iodine, in infectious disease (CTF) 227; in obstetrics/gynecology (CTF) 721
Powell, Stephen H. (author) case report, digoxin toxicity with therapeutic levels, 547; (author) letter of reply, 869
Practolol, pharmacokinetics, 746
Prasolol, in cardiovascular disease (CTF) 642
Prazosin, in cardiovascular disease (CTF) 441, 642, 796
Prednisolone, in gastroenterology (CTF) 379; in pulmonary disease (CTF) 381
Prednisone, in gastroenterology (CTF) 67; in pediatrics (CTF) 798; in renal disease (CTF) 146; relapsing polycondritis, 413; in pulmonary disease (CTF) 873
Pregnancy Tests, false positives (DIAS Rounds) 429
Prescription Drugs, joint commission completes drug use study, 157
Prifinium Bromide, in gastroenterology (CTF) 145
Primidone, pharmacokinetic calculations, 674
Procaine, in anesthesiology (CTF) 302
Procaine Penicillin G, in infectious disease (CTF) 554
Product Problem Reporting Program, ACCP and AANN added, Jan-ctr-4; endorsed by the American Nurses Association, Ju/Aug ctr-1; recognized by FDA, Ju/Aug ctr-1
Progestone, topical, effect on sebaceous gland in acne, 501
Propoxyphene, in renal disease (CTF) 644
Propylthiouracil, bioavailability study, nasal administration (ab) 12, 634; for phantom limb pain, 100; in breast milk, 100; in cardiovascular disease (CTF) 67; in general medicine (CTF) 145; in neurology (CTF) 68; in obstetrics/gynecology (CTF) 146; in psychiatry (CTF) 798; in pregnancy, 100; in psychiatry (CTF) 644; in thyroid storm, 347; in toxicology (CTF) 443; dosing prior to coronary artery bypass surgery, 831
Proprietary Association, self-medication symposium, 815
Propylene Glycol, in dermatology (CTF) 796
Propylthiouracil, in thyroid storm, 347

- Prosen, H.** (coauthor) see **Ahsanuddin, K.**, 288
- Prostaglandin E₁**, in gastroenterology (CTF) 442; in obstetrics/gynecology (CTF) 146, 872
- Prostaglandin F_{2α}**, in obstetrics/gynecology (CTF) 380
- Prostaglandin I₂**, in general medicine (CTF) 379
- Prostaglandin Synthetase Inhibitors**, in pediatrics (CTF) 443
- Prostatic Adenocarcinoma**, in oncology (CTF) 643
- Protein**, in nutrition (CTF) 146, 380
- Provost, George P.** (author) letter, *American College of Clinical Pharmacy: why?*, 293
- Psoriasis**, in dermatology (CTF) 720
- Psychiatry (CTF)**, baclofen, 146; benztropine, 228; caffeine, 68; choline chloride, 68; clonidine, 644; diazepam, 555; hemodialysis, 644, 721; hyperalgesia, 555; leclithin, 146; levodopa/carbidopa, 303; lithium, 68, 304; loxapine, 381; mianserin, 381; propranolol, 644, 798; thioridazine, 721; trinitramine, 304; L-tryptophan, 721; valproate sodium, 228; zometapine, 381; amitriptyline, 873; haloperidol, 873; trimipramine, 873; L-tryptophan, 873
- Psychotropic Drugs**, brochure available, 395
- Pulmonary Disease (CTF)**, antitubercular agents, 644; atropine, 721; cloprednol, 146, 228; cromolyn, 146; diazoxide, 228; dipyridine, 708; hydralazine, 228; isoproterenol, 228; methylprednisolone, 443, 721; prednisolone, 381; pulmonary edema, 644; theophylline, 228; triamcinolone acetonide, 555; tuberculosis, 555; chlorambucil, 873; prednisone, 873; tuberculosis, 873
- Pulmonary Edema**, in pulmonary disease (CTF) 644
- Pyres, Gene D.** (author) simple computation formulas to determine D50W needed to adjust the final dextrose concentrations in intravenous solutions, 870
- Pyridoxine**, adjunct therapy with hexamethylmelamine, 592
- Q**
- Quindine**, algorithm for interaction with digoxin, 57; fever and hepatic dysfunction, 216; in breast milk, 101; in cardiovascular disease (CTF) 553; in pregnancy, 101; interaction with digoxin, 569
- Quinn, Suzanne** (coauthor) Corticosteroid Therapy for Septic Shock: Review and Analysis, 247
- R**
- Rausch, Ralph H.** (author) Clinical Pharmacokinetics of Heparin, 483
- Raber, Jack H.** (author) The Pharmacotherapy of Thyroid Storm, 344 (author) comments on digoxin toxicity, 968
- Rabies Vaccine**, new human vaccine approved, 814; in general medicine (CTF) 871
- Racemethionine**, USP monograph, Fc-ct 4
- Racki, Anthony J.** (author) see **Hayashi, Robert J.**, 189
- Radiation**, in toxicology (CTF) 722
- Radioimmunoassay**, new method for vancomycin (ab 23), 636
- Raehl, Cynthia L.** (coauthor) see **Foster, Thomas S.**, 40, 122, 786
- Randall, Gordon R.** (coauthor) see **Koren, James F.**, 252
- Rapp, Robert E.** (author) chairman, program committee, ACCP, 167 (coauthor) Guidelines for the Administration of Commonly Used Intravenous Drugs, 183 (coauthor) letter, authors' reply to iv guideline correction, 791
- Record, Kenneth E.** (coauthor) see **DiPiro, Joseph T.**, 53
- Referees**, Appreciation to, 896
- Regulations**, pharmaceutical, new information, 694
- Relaxin**, in obstetrics/gynecology (CTF) 380
- Renal Disease**, complication of amphotericin B, 178; long-term use of nandrolone and testosterone, 493; with low dose acetaminophen and halothane anesthesia, 431
- Renal Disease (CTF)** chlorothiazide, 228; chronic renal failure, 644; choline, 721; dihydrochloride, 555; hemodialysis, 798; heparin, 146; methylprednisolone, 555; prednisone, 146; propoxyphene/norpropoxyphene, 644; sulfapyrazole, 555; 25-hydroxyvitamin D₃, 555; zinc, 555; drug therapy, 873; phenytoin, 873; zinc, 873
- Renal Failure**, overview, in renal disease (CTF) 644; pharmacokinetics of cinoxacin (ab 3), 632; with indomethacin (case report) 711
- Research**, informed consent, 122; legal and ethical issues, informed consent, 40; methodologies used in drug product selection studies, 126
- Research Methodology**, 40, 122
- Reserpine**, in thyroid storm, 347
- Reye's Syndrome**, intravenous glycerol therapy (ab 21), 636
- Rheumatology (CTF)**, antiarthritic agents, 443; choline magnesium trisilicate, 443; colchicine, 304; cyclophosphamide, 798; diflunisal, 381, 798; fenofenof, 304; ibuprofen, 229; haloperidol, 644; ibuprofen, 873; indomethacin, 644; levamisole, 443; nonsteroidal antiinflammatory drugs, 443; osmic acid, 443; penicillamine, 146; pneumococcal vaccine, 229; sulfasalazine, 443; sulindac, 68
- Riboflavin**, in nutrition (CTF) 68; ibuprofen, 872
- Riddiough, Michael A.** (author) letter, *American College of Clinical Pharmacy: individual prestige vs professional needs*, 293
- Rietscha, William J.** (coauthor) case report, intravenous lidocaine in the treatment of seizures, 436
- Rifampin**, in infectious disease (CTF) 380
- Ritodrine**, for premature labor, 762; in obstetrics/gynecology (CTF) 767
- Ritschel, Gerda** (author) book review, 564
- Ritschel, W.A.** (author) Compilation of Pharmacokinetic Parameters of Beta-Adrenergic Blocking Agents, 746 (author) book review, 233
- Rittase, Robert A.** (coauthor) letter, see **Sawyer, William T.**, 719
- Roberts, Barry** (author) letter, comments on editorial "Pharmacy, whither goest thou?", 626
- Robinson, J. Daniel** (coauthor) see **Murphy, John E.**, 420
- Rodman, John H.**, budget and finance committee, ACCP, 167
- Rosaramicin**, possible hepatotoxicity, 786
- Rosenfeld, Joseph** (coauthor) case report, see **Grinblatt, Joseph**, 431
- Rossi, Allen C.** (coauthor) see **Knapp, Deanne E.**, 23
- Ruger, James R.** (coauthor) see **Torre, Michael S.**, 222
- Rumack, Barry H.** (coauthor) see **Snodgrass, Wayne**, 783
- Rush, Daniel S.** (coauthor) see **DiPiro, Joseph T.**, 53
- Rymer, William** (coauthor) case report, hypoprothrombinemia associated with cefamandole, 780
- S**
- Saccharin**, bladder cancer update, 462; FDA update, 572
- Safflower Oil**, in nutrition (CTF) 872
- Saiki, James K.** (coauthor) letter, see **Vaziri, Nosratola D.**, 549
- Salad, Stephen R.** (coauthor) letter, see **Ereshefsky, Larry**, 138
- Salem, Ronald B.** (coauthor) case report, ataxia as the primary symptom of lithium toxicity, 622 (coauthor) Investigation of the Crystallization of Phenytoin in Normal Saline, 605
- Salicylates** see also **Aspirin**, differential effects of sodium salicylate and acetylsalicylic acid on cellular cytotoxicity and lymphocyte transformation (ab 14), 635
- Saline**, hypertonic, for phantom limb pain, 100
- Salter, Fred J.** (coauthor) see **Smith, Marie A.**, 169 (author) letter of reply, 868
- Saltiel, Manuel** (coauthor) letter, phenytoin-chloramphenicol interaction, 221
- Sands, Judy E.** (coauthor) see **Lundin, Dorothy V.**, 335
- Sawyer, Dennis** (editor) Current Therapeutic Findings, 441, 796 (coauthor) see **Snodgrass, Wayne**, 783
- Sawyer, William T.** (coauthor) letter, additional problems associated with serum drug levels, 718 (author) letter correction to article on e.c. aspirin bioavailability, 628 (coauthor) see **Bickett, William J.**, II, 103
- Scheuer, Cary L.** (author) letter, comment on drug information sources, 296
- Schneeweiss, Fred** (author) letter, response to comment on drug information sources, 296 (coauthor) letter, acetazolamide metabolic acidosis, 185
- Schobben, F.** (coauthor) see **van der Kleijn, Eppo**, 674
- Schondelmeyer, Stephen W.** (coauthor) Perspectives on Medical Specialization, 30
- Schwartz, Michael A.** (author) The No-B.S. Pharm. D. Degree, 37
- Schwartz, Rowena** (author) comments on metoclopramide review, 467
- Schwinghammer, Terrence L.** (coauthor) letter, see **Kroboth, Patricia Dowley**, 627 (coauthor) see **Britton, H. Lynn**, 546
- Seizures**, adverse reaction to amitriptyline, 378; use of lidocaine (case report) 436
- Self-Medication**, symposium held by proprietary association, 815
- Senility**, may be reversed by drug therapy, 77
- Shimomura, Sam K.** (coauthor) DIAS Rounds, colchicine and reproductive function, 428 (editor) DIAS Rounds, 99, 187, 428, 642
- Shock, septic**, corticosteroid therapy, 247
- Sieradzki, Edmund** (coauthor) see **Wichlinki Leslaw M.**, 765
- Silver Nitrate**, for gonococcal ophthalmia neonatorum, 59
- Simon, Lee S.** (coauthor) see **Falkh, Dev S.**, 126
- Sinca, Thomas S.** (author) book review, 384
- Skilled Nursing Facility**, clinical significance of consultant pharmacist recommendations, 182
- Skinner, William J.** (author) Freedom of Speech and Freedom of the Press in Medical and Pharmacy Practice, 609
- Skontalis, Vasilios A.**, public and professional relations committee, ACCP, 167
- Smallpox**, eradication of, 317
- Smith, Christine L.** (coauthor) letter, see **Sawyer, William T.**, 719
- Smith, Dorothy L.**, public and professional relations committee, ACCP, 167
- Smith, Gary H.** (author) Minoxidil Evaluation, 477
- Smith, Marie A.** (coauthor) Metoclopramide (New Drug Evaluation) 169 (coauthor) letter of reply, 868
- Smith, Mickey C.** (author) Drugs and the Right to Happiness, 108
- Smith, William E., Jr.** (coauthor) The Pharmacy Service of Memorial Hospital Medical Center, 599
- Snader, Thomas C.** (coauthor) see **Quinn, Suzanne**, 247
- Snodgrass, Wayne** (coauthor) case report, asymptomatic theophylline overdose, 783
- SOAR**, screening method for adverse drug reactions, 23
- Social Security Administration**, supplemental security income (SSI) to increase, 573
- Sodium Chloride Phosphate**, in urology (CTF) 229
- Sodium Chloride Injection**, redefined by USP, 11/Aug-ct 3
- Sodium Phosphate**, in endocrinology (CTF) 720
- Sohn, Catherine Angell** (coauthor) Effectiveness of a Cephalosporin Education Program—A Pharmacy Education Program, 272
- Somatostatin**, in gastroenterology (CTF) 554; in general medicine (CTF) 302; in pediatrics (CTF) 380
- Sotalol**, pharmacokinetics, 746
- Specialization**, in clinical pharmacy (ed) 540; medical perspectives, 30
- Spectinomycin**, in pediatrics (CTF) 554
- Spironolactone**, in cardiovascular disease (CTF) 441
- Squamous Cell Carcinoma**, in oncology (CTF) 872
- Sramek, John J.** (author) letter, comments on antipsychotic drugs, 138
- Staphylococcus aureus**, penicillin resistant, in family practice populations, 851
- Stein, Z.L.G.** (author) letter, article on corticosteroid therapy, 719 (author) letter, comments on lithium article, 137
- Stephens, Nancy M.** (coauthor) DIAS Rounds, clonidine for opiate withdrawal, 101 (coauthor) letter, see **Saltiel, Manuel**, 221
- Stewart, Ronald B.**, constitution and bylaws committee, ACCP, 167; credentials committee, ACCP, 167
- Stimmel, Glen L.** (author) book review, 383 (author) Mapline, 585; chairman, public and professional relations committee, ACCP, 167; clinical pharmacy and specialization (ed) 540
- Stranz, Marc H.** (author) Miconazole, 86
- Streptokinase**, in urology (CTF) 69; in cardiovascular disease (CTF) 145
- Strychnine**, in pediatrics (CTF) 644
- Stubblefield, Phillip C.** (coauthor) see **Kaul, Alan F.**, 866
- Sula, Joseph A.** (coauthor) see **Tung, Elizabeth Chow**, 848
- Sulfadiazine**, in obstetrics/gynecology, 872
- Sulfamethoxazole-Trimethoprim**, in infectious disease (CTF) 303
- Sulfasalazine**, in gastroenterology (CTF) 67; in pediatrics (CTF) 443; in rheumatology (CTF) 443
- Sulfipyrazole**, further investigation for heart attack victims, 654; in cardiovascular disease (CTF) 302; in renal disease (CTF) 555
- Sulfonamides**, single dose treatment with UTIs, 187
- Sulindac**, in rheumatology (CTF) 68
- Sullivan, John B., Jr.** (coauthor) see **Snodgrass, Wayne**, 783
- Sunlamps**, FDA regulations, 318
- Swanson, Craig K.** (coauthor) letter, lorazepam withdrawal, 628
- Swanson, Larry N.** (coauthor) see **Mutnick, Alan H.**, 507
- T**
- Talbert, Robert L.** (coauthor) see **Dean, Roger F.**, 864
- Talimolol**, pharmacokinetics, 746
- Talon**, new rodenticide approved by the Environmental Protection Agency, 390
- Tamoxifen**, in oncology (CTF) 68, 643
- Tani, Alan** (coauthor) DIAS Rounds, see **Stephens, Nancy M.**, 100
- Tannenbaum, Renee** (coauthor) see **Meisel, Steven**, 869
- Tanning Booths**, warnings required, 78
- Taylor, Jerry W.** (coauthor) Oral Anticoagulant-Phenytoin Interactions, 669
- Teal, Steven J.** (author) letter, comments on benzodiazepine reaction, 723
- Technologists**, part of pharmacy team (ed), 134
- Tegretol**, in cardiovascular disease (CTF) 441
- Teratogenicity**, in obstetrics/gynecology (CTF) 228
- Terbutaline**, effect on blood glucose, 546; for premature labor, 757; in dermatology (CTF) 379; in pediatrics (CTF) 228; over dosage, 866
- Testosterone**, in pediatrics (CTF) 380
- Tetracycline**, for acne, 499; for gonococcal ophthalmia neonatorum, 59; in oncology (CTF) 146
- Thalidomide**, in dermatology (CTF) 642
- Theophylline**, asymptomatic overdose, 783; avoidance of adverse effects during chronic therapy, 522; effect of erythromycin on blood levels, 528; effect on lithium excretion, 529; effect on migraine headaches, 529; factors affecting elimination, 526; in dermatology (CTF) 379; in pediatrics (CTF) 380; in pulmonary disease (CTF) 228; in toxicology (CTF) 555; inappropriately drawn serum level (table) 220; interaction with phenytoin (ab 31), 638; kinetics, effect of erythromycin (ab 25), 637
- Thiabendazole**, in ophthalmology (CTF) 380
- Thiamphenicol**, in urology (CTF) 798
- Thies, Harold** (coauthor) see **Errick, Jeffrey Keith**, 623
- Thioridazine**, in psychiatry (CTF) 721
- Thompson, Dennis F.** (author) letter, comment on CTF column, 440
- Thompson, Gregory A.** (coauthor) letter, funds transferred to ACCP, 627
- Thordson, Donna J.** (author) book review, 449
- Thrombophlebitis**, reaction to amphotericin B, 179
- Thrombotic Thrombocytopenic Purpura**, in hematology (CTF) 379
- Thyroid**, oral anticoagulant; and drugs which alter function, 331
- Thyroid Hormones**, in endocrinology (CTF) 302
- Thyroid Storm**, management, 346; pharmacotherapy, 344
- Thyroxine**, in toxicology (CTF) 443
- Ticarcillin**, stability in intravenous solutions, 848
- Ticynarone**, recalled and suspended from the market, 158
- Tidekstar, Rein** (author) letter, use of amantadine in the elderly, 377
- Tilles, Jeremiah G.** (coauthor) letter, see **Vaziri, Nosratola D.**, 549
- Timolol**, hypotension following a single dose (ab 1), 632; in cardiovascular disease (CTF) 302; in ophthalmology (CTF) 228, 643; pharmacokinetics, 746
- Tobramycin**, case report, dosing considerations, 55; with cefamandole in infectious disease (CTF) 554
- Tocainide**, in cardiovascular disease (CTF) 796
- Tolamolol**, pharmacokinetics, 746
- Tonelli, Robert J.** (author) letter, journal club comment, 440
- Torossian, George** (coauthor) see **Salem, Ronald B.**, 605
- Torre, Michael S.** (coauthor) letter, pharmacy inservice to OR/RR nursing staff, 222
- Total Parenteral Nutrition**, liver enzyme elevation, 702
- Tourette's Syndrome**, treatment with clonidine, 288
- Toxicity**, asymptomatic theophylline overdose, 783; metoclopramide, 172
- Toxicology (CTF)**, acetaminophen, 381, 443; acetylcysteine, 147; almaline, 69; antidotes, 69; arsenic, 555; butyl nitrite, 555; austics, 381; chloral hydrate, 443; chloramphenicol, 381; clonidine, 69; digoxin, 69; dihydroergotamine, 555; ethylene glycol, 644; glue, 229; hemoperfusion, 69; heroin, 304; hydrocarbons, 644;

ipocac syrup, 644; iron, 796; isobutyl nitrite, 722; isoniazid, 381; loperamide, 722; methanol, 229; metoclopramide, 722; nalidixic acid, 147; naloxone, 147, 443; nitroglycerin, 796; paraquat, 304, 722; pennyroyal oil, 229; phenylethylamine, 304; propranolol, 443; radiation, 722; theophylline, 555; thyroxine, 443; tricyclic antidepressants, 722; valproate sodium, 69; water, 722; acids, 873

Traceray, seizure by FDA, 239

Traveler's Diarrhea, in gastroenterology (CTF) 642

Triamcinolone Acetonide, in pulmonary disease (CTF) 555

Triamterene-Hydrochlorothiazide, not approved by FDA, 654

Triam-thiazide, elevated potassium levels, 395

Triazolam, report of hallucinations, 714

Trichloromethazine, pharmacokinetics in hypertensive patients (ab 28), 657

Tricyclic Antidepressants see also individual drug names, in toxicology (CTF) 722

Trifluoperazine, in gastroenterology (CTF) 871

Trifluoridine, in ophthalmology (CTF) 798

Trimethoprim, in infectious disease (CTF) 720, 797; in pediatrics (CTF) 721

Trimethoprim/Sulfamethoxazole see also Co-trimoxazole; in infectious disease (CTF) 228; in pediatrics (CTF) 380

Trimipramine, in psychiatry (CTF) 304, 873

Trisnel, Lawrence A. (co-editor) Investigational Drug Information

Troleandomycin, effect on theophylline blood levels, 527

L-Tryptophan, in psychiatry (CTF) 721, 873

Tuberculosis, in pulmonary disease (CTF) 555, 873

Tung, Elizabeth Chow (author) Stability of Five Antibiotics in Plastic Intravenous Solution Containers of Dextrose and Sodium Chloride, 548

Twin, Edward J. (coauthor) see Covinsky, Joel O., 266

U

Ultrafiltration, new method, separation of antidiarrhythmics (ab 16), 635

Undecylenic Acid, in dermatology (CTF) 796

United States Pharmacists Political Action Committee, reception, statement by Mickey Leland, 574

United States Pharmacopoeial Convention, "About Your Medicines" distributed to newspapers, *J/Aug* ctr-4; additional associations, *Jan*-ctr 1; building and organization (ed) 430; committee of revision, *June* ctr-3; consumer drug education, *June* ctr-3; exhibits at several conventions, *Jan*-ctr 3; honorary membership, *Fe*-ctr 1; members of revision committee, *J/Aug* ctr-4; new officers elected, *June* ctr-1; new procedures for revision committee, *J/Aug* ctr-2; 1990 meeting notes, *June* ctr-1; nominating committee appointed, *Jan*-ctr 1; officers and trustees elected, *Fe*-ctr 1; pharmacopoeial forum, *Jan*-ctr 2; program for quinquennial meeting, *Fe*-ctr 2; quinquennial meeting, *Jan*-ctr 1; receives FDA honor, *J/Aug* ctr-1; remarks by Mickey Leland, *J/Aug* ctr-3; resolutions committee studies recommendations, *Jan*-ctr 2

U.S. Public Health Service Professional Association, held fifteenth annual meeting, 157

University of Minnesota, college of pharmacy begins program for clinical scientists, 159

Urea, in general medicine (CTF) 797, 871

Urinary Tract Infections, single treatment with antibiotics, 187

Urology (CTF), clomiphene, 798; imipramine, 644; indomethacin, 555; phenoxymethylamine, 722; sodium cellulose phosphate, 229; streptokinase, 69; thiamphenicol, 798; mitomycin C, 873

Ursodeoxycholic Acid, in gastroenterology (CTF) 720

USAN, 1981 available, *June* ctr-4

USF, Dictionary of Drug Names, 1981 available, *June* ctr-4; increasing use by many countries, *J/Aug* ctr-2; redefines sodium chloride injection, *J/Aug* ctr-2

USP-DI Review, a new publication, *Fe*-ctr 3

USP-NF, monograph subscription service, *Fe*-ctr 3; 1980 edition released, *Fe*-ctr 4; first supplement available, *J/Aug* ctr-4; supplements and updates kept current, *Jan*-ctr 4

USP Update, *Jan*-ctr, *Fe*-ctr, *Je*-ctr, *J/Aug*-ctr, *Oct*-ctr

V

Vaccines, viral, FDA endorses use in childhood immunization, 571

Valentic, John (coauthor) letter, see Vaziri, Nosratola D., 549

Valproate Sodium see also Valproic Acid; in psychiatry (CTF) 228; in toxicology (CTF) 69; pharmacokinetic calculations, 674

Valproic Acid see also Valproate Sodium; in neurology (CTF) 442; in pediatrics (CTF) 303, 380; in obstetrics/gynecology (CTF) 872

Vancomycin, comparison of bioassay and radioimmunoassay (ab 23), 636; in infectious disease (CTF) 442; stability in intravenous solutions, 848

van der Kleijn, Eppo (coauthor) Clinical Pharmacokinetics of Antiepileptic Drugs, 674; public and professional relations committee, ACCP, 167

Vasodilators, in cardiovascular disease (CTF) 441, 553

Vaziri, Nick D. (coauthor) see Mirahmadi, Mike K., 493; (coauthor) letter, hemodialysis of erythromycin, 549

Venerical Disease, in general medicine (CTF) 379

Verapamil, in cardiovascular disease (CTF) 302, 553, 796

Vermorken, A. J. M. (coauthor) Acne and Antibiotics, 498

Vincristine, in pediatrics (CTF) 554; lung cancer, 595

Vindesine Sulfate, review, 28

VIPs Bergen, John V., 655; Brands, Allen J., 575; Buc, Nancy L., 463; Carter, Tim Lee, 159; Coleman, Lt. Col. Fred E., 575; Cooper, Theodore H., 734; Del Real, Juan A., 575; Durgin, Sister Jane M., 655; Fay, John T., 655; Feinberg, Max, 159; Goyan, Jere E., 655; Grant, R. Alexander, 159; Greisinger, Edward F., 655; Hackett, Joseph J., 575; Halperin, Jerome A., 575; Hart, Ronald W., 319, 575; Jeffrey, Louis P., 319; Knowles, Mark R., 735; Lantos, Robert L., 655; LaSala, Edward F., 159; Lebow, Morton A., 734; Link, David, 319; Mosso, Joseph A., 159; Nazaria, John, 575; Newman, Howard N., 655; Nicholas, Betram A., 159; Niemrow, Larry, 575; Nightingale, Stuart, 159; Novitch, Mark, 159; Robinson, Sumner, M., 159; Rodricks, Joseph, 159; Schaeffer, Leonard, 655; Sleight, Stephen M., 735; Smith, Mickey C., 575; Studley, Jamieenne, 735; Trygstad, Vernon, 735; Upton, Arthur C., 159; Whitman, James A., 655; Williams, Joseph D., 159; Worthen, Dr. Leonard, 575; Yu, Cheng-Der, 575; Haislip, Gene, 881; Durkin, Kenneth A., 881; Jeffrey, Louis P., 881; DeVita, Vincent T., 881

Vitamin A, in ophthalmology (CTF) 443

Vitamin B₁₂, allergic reaction (case report) 716; in nutrition (CTF) 797

Vitamin E, in hematology (CTF) 720; in nutrition (CTF) 303; in pediatrics (CTF) 228

Vitamins, in nutrition (CTF) 442

Vlasses, Peter H. (coauthor) see Mil'et, Douglas A., 182; (coauthor) see Zappacosta, Anthony R., 373; credentials committee, ACCP, 167

Vree, T.B. (coauthor) see van der Kleijn, Eppo, 674

W

Wade, Lance "C" (coauthor) Combination Mesoridazine- and Benzotropine Mesylate- Induced Paralytic Ileus, 17

Waller, Elaine (coauthor) Dapsone-Induced Hemolytic Anemia in a Patient With Relapsing Polychondritis, 412

Walter, C. W. (coauthor) see Ausman, R.K., 284; (coauthor) see Holmes, C.J., 353

Walton, Charles A., credentials committee, ACCP, 167

Warfarin, in cardiovascular disease (CTF) 67; in obstetrics/gynecology (CTF) 303; interactions with phenytoin, 669; bleeding with metronidazole, 864

Wargin, William A. (coauthor) see Cocchetto, David M., 769

Washington News and Comments, 77, 157, 237, 317, 395, 461, 571, 653, 733, 813, 879

Water, in toxicology (CTF) 722

Watson, Ronald (author) letter, author's reply, 220

Weinberger, Miller (coauthor) see Hendekes, Leslie, 522; (ed) A Time to Abandon the Use of Iodides in the Management of Pulmonary Diseases, 619

Weiner, Bruce (author) Propranolol Dosing Prior to Coronary Bypass Surgery, 831

Wertheimer, Albert L. (author) book review, 382

Whitney, Harvey A.K., Jr. (ed) Accomplishing a Goal for DICP with Specialty Panels, 51; (ed) Clinical Team Role Models are Needed Within Pharmacy, 134; public and professional relations committee, ACCP, 167; (ed) The Application of Gordon Research Conferences to Pharmacy, 710

Wichinski, Leslaw M. (coauthor) Comparative Studies of the Influence of Elevated Serum Lipid Levels on the Pharmacokinetics of Diazepam in Rabbits and Humans, 765

Wightkin, William (coauthor) book review, 232

Williams, Roger L. (coauthor) see Day, Robert L., 358

Winkler, Leslie (coauthor) see Evans, Ronald P., 217

Wolfman, David (coauthor) see Jim, Lucie K., 371

Wolter, Heather A. (coauthor) see Sohn, Catherine Angell, 272

XYZ

X-rays, guidelines for fetal protection, 79; overuse, 239

Yost, Richard L. (coauthor) see Salem, Ronald B., 605

Zappacosta, Anthony R. (coauthor) case report, captopril in refractory malignant hypertension, 373

Zaske, Darwin (author) book review, 561; programs committee, ACCP, 167

Zax, Brian B. (coauthor) see Knapp, Deanne E., 23

Zinc, in dermatology (CTF) 720; in nutrition (CTF) 303; in renal disease (CTF) 555, 873

Zollinger-Ellison Syndrome, in gastroenterology (CTF) 871

Zometapine, in psychiatry (CTF) 381

ADVERTISERS

American Society of Hospital Pharmacists, IPA, Ap-246; My-324; JI-470; D-896

Bristol Laboratories, Cefadyl, Mr-166; Ap-289; My-375; Je-167; S-650; O-701; N-745; D-883; Kantrex, Ja-1, 2; Mexate, je-insert between 72-73; Fe-insert between 120-121; Ap-313, 314; My-325, 326; Je-455, 456; JI-541, 542; S-617, 618; O-659, 660; N-777, 778

Burroughs Wellcome Co., Proloprim, JI-543; Septra DS, Fe-16; N-506-808

Cedpharm, Information-Cedpharm, Mr-186; Ap-277

Ciba-Geigy Corporation, Lopropr, Ja-obc; Fe-obc; Mr-obc

Drug Intelligence and Clinical Pharmacy, AID, Ja-10; Mr-168; Ap-244; My-16; D-876; Bound Volumes, Ja-73; Fe-151; Ap-312; My-394; S-648; D-584; PharmaCE 80, Ja-16c; Fe-16c; Mr-16c; Ap-287; Ap-16c; My-16c; Je-419; JI-16c; S-657; O-16c; N-16c; D-16c; Repertorio Terapeutico, Ja-66; Fe-121; Ap-271; O-729; D-844; Reprints, Ja-73; Fe-151; Mr-236; JI-560; O-730; N-810; D-874; Subscription Information, Mr-208; Ap-265, obc; My-obc; Je-obc; JI-488, 482, obc; S-584, obc; O-685, 728, obc; N-obc; D-884, 895, obc

Drug Intelligence Publications, Audio Courses, Mr-16c; Basic Pharmacokinetics, Ja-70; Mr-226; Multiple Book ad, Fe-154; JI-476; New York Hospital manuals, My-352; Pharmacokinetic Slide Rule, Mr-226; Problems in Pediatric Drug Therapy, Ja-16c; Fe-102

Edite Cantor, Drug Research, Ja-50

Elsevier/North-Holland Biomedical Press, Pharmacy International, Ap-311

Eli Lilly and Company, "I think the response..." Ap-278, 279; My-392, 393; Kefzol, Ja-63; Fe-135; Mr-209; Ap-301; My-343; Je-403; JI-521; S-581; N-779; "When you put a clinical..." Je-445-447; JI-470-472; S-629-631; O-661-663; N-741-743; D-821-823; "With specialized clinical training..." Ja-44, 45; Fe-148, 149; Mr-164, 165

McGraw-Hill Book Company, McGraw-Hill Nursing books, Ap-295

Merrell-National Laboratories, Bentyt, JI-474-476; S-646-648; N-809, 810; Chronulac, Ja-64-66; Fe-142-144; Mr-224-226; JI-556-558; S-582-584; O-726-728; N-800-802

Micromedex Inc., Paul de Haen Information Systems, S-16

Personnel Placement, 71, 152, 234, 312, 394, 460, 566, 648, 730, 875

Roche Laboratories, Representative Training, Ja-6, 7; Fe-140, 141; Mr-230, 231; S-640, 641; O-724, 725; Research Grant Winners, Ap-305-307; My-389-391; Je-431-453; "Speaking Professionally," N-804, 805

Smith, Kline & French Laboratories, Hospital Pharmacy Services, My-376; Je-16c; N-16c

E.R. Squibb & Sons, Inc., Corgard, Fe-96-98; Mr-210-212; Ap-308-309

University of California, Poisoning & Toxicological Emergencies Conference, Fe-107

Viobin Corporation, Viokase, Fe-120; Ap-16c; Je-454; JI-16c; O-16c; D-16c

INDEX ABBREVIATIONS

ab: abstract
CTF: Current Therapeutic Findings
ctr: content insert
edi: editorial
fbc: inside back cover
fci: inside front cover
ofci: outside back cover

